Wayne State University
Wayne State University Dissertations

1-1-2013

Investigation Of Dopamine Dynamics In Bdnf+/Mice Using In Vivo Microdialysis And
Electrochemical Analysis Of Purine And
Monoamine Molecules Using A Boron-Doped
Diamond Electrode
Johnna A. Birbeck
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Recommended Citation
Birbeck, Johnna A., "Investigation Of Dopamine Dynamics In Bdnf+/- Mice Using In Vivo Microdialysis And Electrochemical
Analysis Of Purine And Monoamine Molecules Using A Boron-Doped Diamond Electrode" (2013). Wayne State University
Dissertations. Paper 750.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

INVESTIGATION OF DOPAMINE DYNAMICS IN BDNF+/- MICE USING IN
VIVO MICRODIALYSIS
AND
ELECTROCHEMICAL ANALYSIS OF PURINE AND MONOAMINE
MOLECULES USING A BORON-DOPED DIAMOND ELECTRODE
by
JOHNNA ANN BIRBECK
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY

2013
MAJOR: CHEMISTRY (Analytical)
Approved by:
________________________________
Advisor
Date
________________________________
________________________________
________________________________

DEDICATION
This work is dedicated to my parents William and Lori Courneya, my sisters
Rachel Hale and Samantha Courneya, my husband Rob Birbeck, and also to the loved
ones who passed before seeing me complete my work Grandma Judith Greenwood,
Uncle Brendt Greenwood, Aunt Beverly Courneya, and Grandma Charlotte Courneya.
Thank you for your continued support, encouragement, compassion, and love.

ii

ACKNOWLEDGEMENTS
I would first and foremost like to thank my advisor Dr. Tiffany Mathews, for all of
her advice, support, and guidance. She helped mold me into the scientist that I have
become, encouraged me to try new experiments without fear, and never lost faith in me.
She went above and beyond her duties as a mentor to make my time here at Wayne
State University a success. To my undergraduate advisor, Dr. Judy Westrick, who
believed in me from the start and encouraged me to not only get a bachelor’s degree in
chemistry, but to also go to graduate school. I wouldn’t be here if it wasn’t for her. And
to my dissertation committee, Dr. Sarah Trimpin, Dr. John Santa Lucia, and Dr. Scott
Bowen, thank you for your advice, comments, and support which greatly impacted my
research, making it stronger and more complete.
I would graciously like to thank my lab members Dr. Kelly Bosse, Dr. Francis
Maina, Dr. Madiha Khalid, for all of your help in collaboration with the BDNF projects in
order to gain a more comprehensive understanding for each project. To Dr. Madiha
Khalid, thank you for all of the encouragement and support as we traveled this journey
together. And to my current lab members Brooke and Aaron, and past Dr. Jamie Carroll,
Dr. Rabab Aoun, Stella, Katie, Chris, Joe, Michelle, Stephanie, and Doug who always
kept the lab fun, interesting, and full of good times and memories.
Most importantly, I would like to thank my parents, William and Lori, and my
sisters Rachel and Samantha for always being supportive and encouraging me through
this journey. And lastly to my husband, Rob, thank you for listening to my presentations,
your help in reading my many manuscripts for clarity, and for being my rock when I
needed it most. I couldn’t have done this without you. I love you always and forever.

iii

TABLE OF CONTENTS
Dedication………………………………………………………………………………………..ii
Acknowledgments………………………………………………………………………………iii
List of Tables…………………………………………………………………………………….ix
List of Figures……………………………………………………………………………………x
Abbreviations………….………………………………………………………………………..xii
Contributions……………………………………………………………………………………xv
CHAPTER 1: Introduction and Overview……………………………………………………..1
1.1 Neurochemistry……………………………………………………………………..1
1.1.1 Neurotransmission………………………………………………………1
1.1.2 Dopamine………………………………………………………………...2
1.1.3 Adenosine………………………………………………………………..6
1.1.4 Dopamine and adenosine system interactions……………………..10
1.1.5 Brain-derived neurotrophic factor…………………………………….11
1.1.6 Brain-derived neurotrophic factor, the dopamine system, gender
and age…………………………………………………………………12
1.2 Neurochemical techniques……………………………………………………….13
1.2.1 Microdialysis……………………………………………………………13
1.2.2 Electrochemical detection…………………………………………….18
1.2.3 Slice fast scan cyclic voltammetry…………………………………...21
1.2.4 Locomotor activity……………………………………………………..23
1.3 Research objectives………………………………………………………………24

iv

1.3.1 Objective 1: Characterization of the dopamine system in female
BDNF+/- mice………………..…………….…………………………...24
1.3.2 Objective 2: Characterization of the dopamine system in aged
BDNF+/- mice………………………………………………….………..25
1.3.3 Objective 3: Method development for the simultaneous detection of
purine and monoamine molecules using a boron-doped diamond
electrode………………………………………………………………..26
CHAPTER 2: Materials and Methods……………………………………………..………...28
2.1 Chemicals.………………………………………………………………………….28
2.2 Animals…………………………………………………………………………...……….28
2.3 Genotyping……………………………………………………...………………….……..29
2.4 In vivo microdialysis.………………………………………………………..……..32
2.4.1 Surgery…………………………………………………………….……..32
2.4.2 Microdialysis experiments………………………………………..…….33
2.5 Slice fast scan cyclic voltammetry………………………………………..……..35
2.6 Tissue content……………………………………………………………….…….37
2.7 HPLC and electrochemical detection……………………………………..…….37
2.7.1 Detection of neurotransmitters using a porous carbon working
electrode……..………………………………………………..….…….37
2.7.2 Detection of neurotransmitters using a boron-doped diamond
working electrode……………………………………………….……..38
2.8 Locomotor activity…………………………………………………………...…….39
2.9 Statistical analysis.…..…………………………………………………………….40

v

CHAPTER 3: Potentiated striatal dopamine release leads to female BDNF+/- mice
hyperdopaminergia………………..………………...…………………..……42
3.1 Introduction…………………………………………………………...………....…42
3.2 Results and Discussion.……………………………………………………….….43
3.2.1 Elevated basal striatal DA levels in female BDNF+/- mice……….….43
3.2.2 DA metabolites are not different across genotypes.………………....45
3.2.3 Slice FSCV: DA release is elevated in the female BDNF+/- mice.......46
3.2.4 Stimulated DA release via microdialysis is potentiated in the female
BDNF+/- mice…………………………………………………………....48
3.2.5 Methamphetamine-stimulated DA release via microdialysis is
potentiated in the female BDNF+/- mice………………………………49
3.3 Conclusions………………………………………………………………………..52
3.4 Materials and Methods…………………………………………………………...53
3.4.1 Mice………………………………………………………………………53
3.4.2 Microdialysis: Surgery and Experimentation………………...……….53
3.4.3 Slice fast scan cyclic voltammetry…………………………………….55
3.4.4 Statistical Analysis……………………………………………………...56
CHAPTER 4: Normalized striatal dopamine dynamics in aged BDNF deficient mice.…58
4.1 Introduction………………………………………………………………………...58
4.2 Methods…………………………………………………………………………….60
4.2.1 Animals.…………………………………………………………………..60
4.2.2 Microdialysis……………………………………………………………..61

vi

4.2.3 Slice voltammetry………………………………………………………..62
4.2.4 Locomotor activity……………………………………………………….65
4.2.5 Statistical analysis……………………………………………………….65
4.3 Results.…………………………….……………………………………………….66
4.4 Discussion………………………………………………………………………….74
CHAPTER 5: Simultaneous detection of monoamine and purine molecules using a
boron-doped diamond electrode………..…………….…………………….82
5.1 Introduction………………………………………………………………………...82
5.2 Materials and Methods…………………………………………………….…..…85
5.2.1 Chemicals.………………………………………………………………..85
5.2.2 Analytical parameters.…………………………………………………..85
5.2.3 Tissue content.…………………………………………………………..86
5.3 Results and Discussion…………………………………………………………..87
5.3.1 Electrode Characterization……………………………………………..87
5.3.2 Mobile Phase Parameters……………………………………………...88
5.3.3 Hydrodynamic Voltammogram………………………………………...89
5.3.4 Linearity…………………………………………………………………..90
5.3.5 Limits of Detection and Quantification.………………………………..92
5.3.6 Precision and Accuracy………………………………………………...93
5.3.7 Analysis of Monoamine and Purine Neurotransmitters.……………..94
5.4 Conclusions………………………………………………………………………100
CHAPTER 6: Conclusions and Future Directions………………………………………...101
6.1 Characterization of striatal dopamine dynamics in female BDNF+/- mice….102

vii

6.2 Characterization of a lifelong reduction of brain-derived neurotrophic factor
effects on the dopaminergic system in aged BDNF+/- mice………………...103
6.3 Simultaneous detection of dopamine and adenosine using HPLC with
electrochemical detection using a boron-doped diamond electrode………107
References……………………………………………………………………………………110
Abstract………………………………………………………………………………………..135
Autobiographical Statement…………………………………………………………………137

viii

LIST OF TABLES
Table 4.1 Striatal DA dynamics compared between young (3 month) and aged (18
month) mice…………………………………………………………………..……75
Table 5.1 Figures of merit for the simultaneous detection of dopamine (DA) and
adenosine (Ado) using high-performance liquid chromatography (HPLC) with
boron-doped diamond (BDD) electrode…………………………………………93
Table 5.2 Comparison of BDD electrode and carbon electrode for the detection of
monoamine and purine molecules………………………………………………97
Table 5.3 Comparison of tissue content from literature…………………………………...99

ix

LIST OF FIGURES
Figure 1.1 Dopamine (DA) synthesis and metabolism……………………………………..4
Figure 1.2 The DA synapse…………………………………………………………………...5
Figure 1.3 DA and Adenosine (Ado) synapse……………………………………………….8
Figure 1.4 Synthesis of Ado from ATP……………………………………………………….9
Figure 1.5 Generation of Ado from S-adenosylhomocysteine……………………………10
Figure 1.6 Schematic of a concentric microdialysis probe……………….…………….....14
Figure 1.7 Representative setup for in vivo microdialysis sample collection…………...18
Figure 1.8 Oxidation and reduction of DA…………………………………………………..22
Figure 1.9 Schematic of a locomotor activity chamber……………………………………24
Figure 2.1 Representative gel electrophoresis image of genotypic identification for
wildtype and BDNF+/- mice……………..………………………………………32
Figure 2.2 Structure of methamphetamine (METH)………………………………………..34
Figure 3.1 Extracellular DA concentration as measured by zero-net flux……………….45
Figure 3.2 Extracellular DA metabolite levels as measured my microdialysis………….46
Figure 3.3 DA release and uptake in the CPu of female mice as measured by slice fast
scan cyclic voltammetry (FSCV)……..………………………………………...47
Figure 3.4 High potassium (K+) stimulated DA release from the CPu…………………..48
Figure 3.5 Methamphetamine (METH) stimulated striatal DA release…..………….…..51
Figure 4.1 Monthly weights of wildtype and BDNF+/- mice………………………………..67
Figure 4.2 Homecage locomotor activity for wildtype and BDNF+/- mice………………..68
Figure 4.3 DA zero-net flux results in aged wildtype and BDNF+/- mice………………...69
Figure 4.4 Extracellular levels of DA and its metabolites in aged mice………………....70
Figure 4.5 Slice FSCV results of presynaptic striatal DA dynamics in aged mice……..73

x

Figure 4.6 Influence of METH on striatal DA dynamics and locomotor behavior in aged
mice..............................................................................................................74
Figure 5.1 Schematic amperometric cell design for the boron-doped diamond electrode
(BDD) and SEM image of the BDD surface……………………………………88
Figure 5.2 Hydrodynamic voltammogram of DA and Ado……………..………………….90
Figure 5.3 Linear calibration curve for the oxidation of Ado and DA……………………..91
Figure 5.4 Representative standard chromatogram and striatal tissue content
chromatogram……………………………………………………………………95

xi

ABBREVIATIONS
3-MT

3-methoxytyramine

5-HIAA

5-hydroxyindoleacetic acid

5-HT

serotonin

AADC

L-aromatic amino acid decarboxylase

aCSF

artificial cerebral spinal fluid

ADHA

attention deficit hyperactivity disorder

Ado

adenosine

ADP

adenosine diphosphate

AMP

adenosine monophosphate

ANOVA

analysis of variance

ATP

adenosine triphosphate

BDD

boron-doped diamond

BDNF

brain-derived neurotrophic factor

BDNF+/-

brain-derived neurotrophic factor heterozygous

BDNF-/-

brain-derived neurotrophic factor knockout

bp

base pairs

cAMP

cyclic adenosine monophosphate

COMT

catechol-o-methyltransferase

CPu

caudate-putamen

DA

dopamine

DAT

dopamine transporter

dNTP

deoxyribonucleotide triphosphate

dATP

2’-deoxyadenosine triphosphate

dCTP

2’-deoxycytidine triphosphate

xii

dGTP

2’-deoxyguanosine triphosphate

DNA

deoxyribonucleic acid

dTTP

deoxythymidine triphosphate

DOPAC

3,4-dihydroxyphenylacetic acid

Ed

extraction fraction

EDTA

ethylenediaminetetraacetic acid

ENT

equilibrative nucleoside transporters

f

frequency

FC

frontal cortex

FSCV

fast scan cyclic voltammetry

GABA

γ-aminobutyric acid

GDNF

glial derived neurotrophic factor

GPCR

G protein-coupled receptor

HPLC

high-performance liquid chromatography

HVA

homovanillic acid

i.p.

intraperitoneal

IR

infrared

kDA

kilo Dalton

Km

Michaelis-Menton constant

Ki

inhibition constant

L-DOPA

L-3,4-dihydroxyphenylalanine

MAO

monoamine oxidase

METH

methamphetamine

MPP+

1-methyl-4-phenylpyridinium

MPTP

1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine

xiii

mRNA

messenger ribonucleic acid

NAc

nucleus accumbens

NDA

naphthalene-2,3-dicarboxaldehyde

NE

norepinephrine

NGF

nerve growth factor

NT

neurotrophin

NT-4

neurotrophin 4

OPA

o-phthalaldehyde

p

pulse

PCR

polymerase chain reaction

Ras

GTP binding protein

rcf

relative centrifugal force

ROS

reactive oxygen species

RNA

ribonucleic acid

SEM

standard error of the mean

SN

substantia nigra

TE

tris-EDTA

TH

tyrosine hydroxylase

TrkB

tyrosine kinase B

UV

ultraviolet

VMAT

vesicular monoamine transporter

VNUT

vesicular nucleotide transporter

V max

maximum velocity

VTA

ventral tegmental area

WT

wildtype

xiv

CONTRIBUTIONS
Chapter 2: Materials and Methods
For all experiments throughout this dissertation that utilized brain-derived
neurotrophic factor (BDNF) heterozygous mice and wildtype mice, in-house breeding,
weaning, genotypic identifications were required. The procedures for the breeding,
weaning, and genotypic analysis were performed by Kelly E. Bosse, Ph.D. and Brooke
Neman. Assistance with these procedures was provided by Katie Logan, Parvejz Khan,
Natasha Bohin, Andrezj Czaja, Christopher Rogalla, Michelle Colombo, Stephanie
Godden, and myself. Experiments and analysis that involved slice fast scan cyclic
voltammetry (FSCV) were conducted by Francis K. Maina, Ph.D. (aged mice), or
Madiha Khalid, Ph.D. (female mice). I performed all experiments and analysis that
involved in vivo microdialysis or locomotor activity.
Chapter 3: Potentiated striatal dopamine release leads to female BDNF+/- mice
hyperdopaminergia
In this chapter, all work done with slice voltammetry experimentation and
analysis was conducted by Madiha Khalid, Ph.D. I performed all microdialysis
experiments and analysis. I also performed all of the required literature search and
manuscript writing, which was submitted to ACS Chemical Neuroscience.
Chapter 4: Normalized striatal dopamine dynamics in aged BDNF deficient mice
Francis K. Maina, Ph.D. conducted all slice FSCV experiments and analysis for
the aged BDNF+/- mice and their wildtype littermates. I performed all microdialysis, and
locomotor activity experiments and analysis. Further help with analysis for
methamphetamine locomotor activity was provided by Scott E. Bowen, Ph.D. Literature

xv

search and manuscript writing was also conducted by myself, and is in revision to The
Neurobiology of Aging.
Chapter 5: Simultaneous detection of monoamine and purine molecules using a
boron-doped diamond electrode
I performed all mobile phase configurations, analytical parameters, tissue content
analysis, as well as figures of merit calculations for this chapter. Furthermore, I wrote
and performed the literature search for the manuscript which was accepted to Analytical
Chemistry.

xvi

1

CHAPTER 1
Introduction and Overview
1.1 Neurochemistry
1.1.1 Neurotransmission
The brain is a complex and organized structure containing greater than 100
billion neurons, with each neuron having its own unique structure and function. Neurons
are complex, with no one neuron being the same and each one being asymmetric.
Although all neurons are unique from one another, they all consist of the same three
major components: cell body, axon, and dendrites. The cell body, also known as the
soma, is the smallest part of the neuron in terms of area and contains the nucleus and
other cytoplasmic organelles. The cell body is responsible for synthesizing and
processing proteins. The axon of a neuron extends out from the cell body as a thin
tubular outgrowth, and it is responsible for conducting electrical impulses to the
terminals. Finally, the dendrites are multiple fine outgrowths (much smaller than the
axon) off of the cell body, and serve as reception sites for other synaptic contacts from
nearby neurons.
The small gap (~5–10 nm) between neurons, known as the synaptic cleft, allows
for chemical messengers (neurotransmitters) to diffuse across the synapse for chemical
communication to occur between the neurons. Upon release from the presynaptic
terminal, neurotransmitters diffuse across the synaptic cleft, bind to specific receptors
on the pre- or postsynaptic terminal, and are either metabolized by enzymes, or are
taken back up into presynaptic neuron by its specific transporter. For a molecule to be
defined as a neurotransmitter it must meet four conditions, 1) synthesis of the molecule
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in a neuron, 2) neuronal release that modulates and affects other nearby neurons, 3)
exogenous application of the molecule mimics the action of the released molecule, and
4) mechanism for the removal of the molecule from the action site. The molecules that
meet these conditions are known as classical neurotransmitters, and examples of the
most commonly studied are the monoamines dopamine (DA), norepinephrine (NE), and
serotonin (5-HT), and the amino acids glutamate and gamma-aminobutyric acid
(GABA). Recently, other molecules have been classified as ‘atypical’ neurotransmitters
because they do not meet the conditions that define classical neurotransmitters.
Chemical molecules defined as ‘atypical’ neurotransmitters include purines adenosine
(Ado) and adenosine triphosphate (ATP), and gases nitric oxide and carbon monoxide.
1.1.2 Dopamine
DA is a member of the monoamine neurotransmitter family, which includes the
molecules epinephrine, NE, 5-HT, and histamine. DA is one of the most studied
neurotransmitters within the brain because of its role in memory, motor behavior,
motivation, reward pathways, and learning as well as playing a key role in neurological
diseases and disorders such as attention deficit hyperactivity disorder (ADHD),
addiction, schizophrenia, Parkinson’s disease, and Huntington’s disease (1-5). In the
brain, DA cell bodies are located in two specific regions, the substantia nigra (SN) and
the ventral tegmental area (VTA), and their axons terminate to various anterior areas of
the brain. The three dominant dopaminergic pathways are the nigrostriatal, mesolimbic,
and mesocortical pathways. The nigrostriatal pathway projects DA from the cell bodies
in the SN to the caudate-putamen (CPu). The mesolimbic pathway carries DA from the
VTA to the nucleus accumbens (NAc). Lastly, the mesocortical pathway transports DA
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from the VTA to the frontal cortex. The nigrostriatal pathway is the key pathway for
learning and motor control, while the mesolimbic pathway is known for its involvement in
reward, motivation, as well emotions such as pleasure and aggression (2, 6).
DA is synthesized in the neuron from L-tyrosine in a two-step process (Figure
1.1). L-Tyrosine is hydroxylated by tyrosine hydroxylase (TH), the rate-limiting step, to
form L-dihydroxyphenylalanine (L-DOPA), which is converted to DA by L-aromatic
amino acid decarboxylase (AADC). After the formation of DA, it is packaged into
storage vesicles by the vesicular monoamine transporter (VMAT), making DA readily
available for rapid release in response to an action potential. Upon release into the
synaptic cleft, DA has a variety of fates that include binding to DA pre- and postsynaptic
receptors, being recycled via the DA transporter (DAT), or diffusing out of the synaptic
cleft into the extracellular space. The DA transporter is a 12-transmembrane protein that
brings DA back into the neuron through an energy dependent mechanism requiring cotransport of two Na+ ions and one extracellular Cl- ion. The presence of the DAT on a
neuron indicates that the neuron is a dopaminergic neuron. Once DA is in the cytosol,
DA is repackaged by VMAT into vesicles where it is readily available for release (Figure
1.2)

4

Figure 1.1 DA synthesis and metabolism.
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Figure 1.2 The DA synapse. DA is synthesized in the presynaptic terminal where it is
packaged into vesicles by VMAT. Upon an action potential DA is released from the
vesicles into the extracellular space where it can be metabolized by MAO or COMT, be
brought back into the presynaptic terminal by DAT, act upon DA pre- and postsynaptic
DA receptors, or diffuse out of the synaptic terminal.
Metabolism of DA is one method for decreasing extracellular DA, and the
enzymes that are responsible for DA metabolism are monoamine oxidase (MAO) and
catechol-o-methyltransferase (COMT). MAO degrades DA by cleaving the amine group
and adding a carboxylic acid group in its place, while COMT methylates the hydroxyl
group meta to the ethylamine group. When DA is metabolized in a stepwise fashion,
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MAO degrades DA to 3, 4-dihydroxyphenylacetic acid (DOPAC), and then COMT acts
upon DOPAC to form homovanillic acid (HVA) (Figure 1.1). Alternatively, COMT acts
directly on DA to form 3-methoxytyramine (3-MT), which MAO can degrade to HVA
(Figure 1.1).
Upon DA release into the synaptic cleft, the primary role of DA is to send a
chemical message from one neuron (presynaptic) to a receiving neuron (postsynaptic).
To date, there are five known DA receptors that belong to a family of seven
transmembrane G-protein coupled receptors (GPCRs). These DA receptors are
separated into two groups: DA D1-like receptors and the D2-like receptors. The D1-like
receptors include receptors D1 and D5 and are coupled to the stimulatory Gs protein that
stimulates adenylyl cyclase, which activates signals to second messengers such as
cyclic adenosine monophosphate (cAMP). The D2-like family includes D2, D3, and D4
receptors that are coupled to the inhibitory Gi/o protein, inhibiting adenylyl cyclase. When
DA receptors are located on a presynaptic DA neuron, they are referred to as
autoreceptors. In essence, DA autoreceptors are constantly monitoring the extracellular
environment and depending on the extracellular DA levels, activation of the
autoreceptor can either induce or inhibit DA release. For instance, activation of DA D2like receptors has been known to decrease the release of DA from the presynaptic
terminal by a feedback inhibition mechanism (7, 8).
1.1.3 Adenosine
Although classical neurotransmitters were defined strictly as acetylcholine,
monoamines, and amino acids, improvements on detection technologies through
instrumentation development has led to the discovery of numerous other biologically
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relevant molecules and measured on a routine basis. Neurotransmitters that do not fall
into the classical neurotransmitter group are referred to as atypical neurotransmitters.
Members of the purine family have long been recognized as important biological
molecules, particularly in the role of energy metabolism. Adenosine (Ado) has long been
considered a neuromodulator and most recently has been described as an atypical
neurotransmitter (2). Ado is a member of the purine family, which includes molecules
such as adenosine monophosphate (AMP), adenosine diphosphate (ADP), and
adenosine triphosphate (ATP). Molecules within the purinergic system are often
characterized as intracellular signaling molecules or as the primary building blocks to
RNA and DNA. As a result few techniques have been developed for sensitive
quantification of these molecules, particularly in terms of their extracellular
concentration (9). Despite the classification as predominantly intracellular molecules,
there is increasing evidence that many of these purine molecules, such as Ado, are key
extracellular signaling molecules (10-12). As an intracellular and extracellular signaling
molecule, determining Ado’s extracellular concentration is critical to understanding how
Ado behaves as an extracellular signaling molecule.
A debate throughout the literature is exactly how Ado is released from the
neuronal cells. One mechanism of extracellular Ado release into the synaptic cleft is by
the fast conversion of ATP to Ado. Cytosolic ATP is packaged into vesicles by the
vesicular nucleotide transporter (VNUT: Figure 1.3) in a similar fashion as classical
neurotransmitters (e.g. DA) (13). Upon neuronal stimulation, ATP is released from the
neuron into the synaptic cleft where ecto-nucleotidases degrade ATP to produce ADP,
and henceforth degrade ADP to AMP. AMP is degraded by ecto-5’-nucleotidase to
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generate Ado (Figure 1.4). Whether intra- or extracellularly, the breakdown of ATP to
Ado is proposed to be completed in less than one second (2). Additionally, a small
portion of Ado is also generated through the metabolism of S-adenosylhomocysteine
(Figures 1.3 and 1.5) (14-17). Cytosolic Ado is then released into extracellular space by
equilibrative nucleoside transporters (ENTs).

Figure 1.3 The DA and Ado synapse. ATP in the presynaptic neuron is packaged into
vesicles via the VNUT, and is released by an action potential into the synaptic cleft.
Once ATP reaches the extracellular space, ecto-nucleotidases degrade ATP to Ado.
Intracellular Ado is formed by two mechanisms, degradation of ATP to Ado, and by the
degradation of S-adenosylhomocysteine.
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Figure 1.4 Synthesis of Ado from ATP. ATP and ADP are degraded by ectonucleotidases or by hydrolysis with water to form ADP or AMP, respectively. The
conversion of Ado is achieved by AMP being degraded by ecto-5’nucleotidase.
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Figure 1.5 Generation of Ado from S-adenosylhomocysteine. S-adenosylhomocysteine
is hydrolyzed by S-adenosylhomocysteine hydrolase to form Ado and homocysteine.
1.1.4 Dopamine and adenosine system interactions
The DA and Ado systems appear to be similarly intertwined with respect to their
receptors. DA has two families of receptors; D1-like and D2-like, while purine P1
receptors (also known as Ado receptors) have at least four distinct subtypes: A1, A2A,
A2B, and A3. Ado A1 (coupled to Gi) and A2A (coupled to Gs) receptors are ubiquitous
throughout the brain. The largest densities of A2A receptors are concentrated in the
dorsal striatum and NAc, which are highly innervated via the DA system. In the dorsal
striatal complex, the D2 and A2A receptors have reciprocal interactions (2, 18). For
example, A2A agonists appear to inhibit the D2 receptor and invoke behaviors similar to
D2 antagonists (2). The ability of purine receptors to evoke DA-like behaviors has
prompted the investigation of specific A2A antagonist as possible therapeutic treatment
for Parkinson’s disease (2). Parkinson’s disease is characterized by a loss of more than
80% of dopaminergic neurons. Dopaminergic therapies are used to treat Parkinson’s
disease such as treatment DA precursor L-DOPA, which attempts to restore
dopaminergic function. However, there are limitations to L-DOPA treatment such as
dyskinesia, hallucinations, on-off effects, and treatment with L-DOPA becomes less
efficacious the longer it is administered (19). As a result, researchers are trying to
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discover alternative therapies such as modulating the dopaminergic system indirectly
through other neurotransmitter systems. A2A antagonists reverse the motor effects
associated with Parkinson’s disease, and appear to do so without dyskinesia, a
predominant side effect from L-DOPA treatment (20).
1.1.5 Brain-derived neurotrophic factor
The classical belief was that neurons communicate with one another by small
molecules like neurotransmitters. However, within the last few decades it has been
recognized there are numerous molecules that can influence neurons such as gases
like carbon dioxide or nitric oxide or proteins such as neurotrophic factors.
Neurotrophins are known for their trophic properties of supporting neuronal cell growth,
differentiation, and survival. Brain-derived neurotrophic factor (BDNF), a 27 kDa protein,
was first discovered in 1982, and belongs to the neurotrophic family, which includes the
neurotrophins nerve growth factor (NGF), neurotrophin-3, neurotrophin-4 (NT-4), and
glial-derived neurotrophic factor (GDNF) (21). Of these neurotrophic factors, BDNF is
most abundant in the brain and appears to be essential in the early development of the
brain (22, 23). BDNF mediates its signaling through its receptor tyrosine kinase B
(TrkB), and the TrkB receptors are expressed in DA rich regions such as the striatum,
SN, and VTA (24). To better understand BDNF’s role in the brain, BDNF knockout mice
were developed, but mice that completely lack (BDNF-/-) cannot survive 21 days after
birth, highlighting the importance of BDNF in species survival (22, 25). BDNF
heterozygous (BDNF+/-) mice developed by Ernfors and colleagues have a 50 %
reduction in both BDNF protein and mRNA levels, and have no phenotypic differences
when compared to their wildtype littermates (25).
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1.1.6 Brain-derived neurotrophic factor, the dopamine system, gender, and aging
With ~13% of the American population over the age of 65, it is becoming
increasingly important to understand the aging process and the diseases that are
associated with having a higher incidence in the elderly population such as Parkinson’s
and Alzheimer’s disease (2010 Census). Since Parkinson’s disease mainly affects the
dopaminergic system, considerable attention has been given to DA. It is well known that
other molecules or proteins may contribute to or play a role in the development and
progression of Parkinson’s disease. Besides DA, one molecule that has garnered
particular attention with respect to Parkinson’s disease is BDNF. Postmortem studies in
Parkinson’s disease patients brain cultures show that BDNF mRNA expression is
significantly reduced in DA neurons in the SN pars compacta (26). Other postmortem
studies corroborate this reduction in mRNA expression as BDNF protein levels are
decreased in the striatum of Parkinson’s disease patients compared to non-Parkinson’s
patients (27). One of the main reasons for interest in BDNF expression and levels with
Parkinson’s patients lies with its interactions with DA. Many studies have alluded to
BDNFs importance in protecting the dopaminergic system since exogenously applied
BDNF is protective prior to a neurotoxic insult. Thus, BDNF administration maintains the
viability of DA neurons in the striatum (26, 28-30). For example, an in vivo infusion of
BDNF increases DA release and enhances DA turnover (31, 32). While a reduction in
endogenous BDNF correlates to a decrease in DA D3 receptor expression in DA rich
brain regions such as the NAc and CPu (33). Furthermore, autoradiography from
postmortem Parkinson’s disease tissue showed a reduction in DA D3 receptor
expression (34). Taken together, there appears to be a complex relationship between
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BDNF and DA, and a dysregulation in one or both systems may increase susceptibility
to Parkinson’s disease.
The risks of developing a particular neurological disease and/or disorder appear
to be different in men and women. For example, men are ~1.5 times more likely to
develop Parkinson’s disease compared to women (35). These susceptibility differences
in developing a particular neurological condition with respect to gender have been
linked to a dysregulation of DA and BDNF, as well as estrogen (36-38). Unfortunately,
to date few animal studies have fully characterized the effect of low endogenous BDNF
levels on the DA system with respect to gender hormones such as estrogen and
testosterone.
1.2 Neurochemical techniques
1.2.1 Microdialysis
Microdialysis is an in vivo sampling technique based on diffusion where
extracellular neurotransmitters diffuse down their concentration gradient towards the
microdialysis probe. Once the extracellular neurotransmitters are collected, the next
step is to analyze them to determine their extracellular levels in a given brain region.
There are numerous geometries of microdialysis probes, which are often chosen
depending on the tissue that will be sampled. For neurochemical measurements,
concentric probes are most commonly used since they are small in length (1–2 mm)
and diameter (240–350 µm), allowing for them to be easily, and accurately placed into a
specific brain region of interest for analysis (39, 40). The perfusate, which is a
physiological buffer resembling the fluid in the extracellular space (artificial cerebral
spinal fluid, aCSF) is perfused continuously through the inlet of the probe (Figure 1.6).
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Dialysate samples are collected from the outlet line where the dialysate sample contains
the neurotransmitters of interest. The microdialysis probe is made of a semi-permeable
membrane that allows small molecules (< 6 kDa in our experiments) to flow down their
concentration gradients and into the probe.

Figure 1.6 Schematic of a concentric microdialysis probe with enlarged image of semipermeable membrane.
There are numerous methodological experiments that can be performed with the
microdialysis probe that ultimately depends on the type of data the researcher is
interested in collecting. The most common method using a microdialysis probe is known
as conventional microdialysis, where the experimenter examines the dialysate directly
with no modification to the sampling technique (41). However, a limitation of the
conventional method is that it underestimates the extracellular neurotransmitter levels.
This is because the microdialysis probe is not recovering 100% of the analyte of interest
from the brain, only a small percentage. Recovery from the microdialysis probe is
influenced by multiple parameters such as perfusion flow rate, sample volume, and
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temporal resolution capabilities. Recovery is defined as relative recovery or absolute
recovery, where relative recovery is the concentration of the analyte in the dialysis
sample divided by the concentration of the sample media, while absolute recovery
pertains to the total analyte mass during the collection period (42). For example,
recovery can be altered as a result of changes in flow rate, where the flow rate
increases, the sample volume increases, while the time required to collect the sample is
reduced. However, when increasing the flow rate, the relative recovery of the analyte is
significantly reduced, which is a result of depleting the analyte of interest in the
extracellular space near the dialysis probe, while the absolute recovery increases. Since
the analyte in the extracellular space is being swept away at a greater rate, there is not
adequate enough time to replenish the analyte of interest, and thus reducing the relative
recovery. Yet, reducing the flow rate has its own limitations such as longer collection
times making analysis slower and decreased temporal resolution. Therefore, a balance
between flow rate and adequate sample volume for the analytical detection technique
must be made while providing a reasonable amount of time to collect a physiologically
relevant sample.
Retrodialysis is an alternative microdialysis method that uses the probe to
deliver an analyte or drug to the brain region of interest. The method of zero-net flux is a
retrodialysis method that delivers various known quantities of an analyte of interest (e.g.
DA), thus enabling one to estimate ‘true’ basal levels. The zero-net flux method uses
linear regression analysis with the measurements from amount of DA entering the probe
(DAin) and the amount of DA leaving the probe (DAout), and the point where the flux of
DA leaving and entering the probe is deemed the point at which there is zero-net
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diffusion across the probe and mathematically this is observed when the line crosses
the x-axis. The point at where no diffusion is occurring through the probe indicates the
‘true’ concentration (or basal, where it has been corrected) at which the analyte is found
in that specific region. Microdialysis itself is an analytical technique that separated
molecules based on molecular weight, where molecules less than a particular cut-off
weight can easily pass through the probe, while those with a larger molecular weight are
excluded. However, microdialysis by itself does not quantitate the neurotransmitter
levels in a sample. Therefore, the type of instrumental analysis is key for the proper
separation, and detection of neurotransmitters from a dialysis sample. Analysis of
dialysate samples begins with a separation component using high-performance liquid
chromatography (HPLC) or capillary electrophoresis and then detected either by
electrochemical detection, mass spectrometry (MS), or fluorescence detection (42).
An advantage of microdialysis sampling is its ability to collect a diverse number
of analytes from the brain, and when coupled to the appropriate analytical method can
separate and detect specific neurotransmitters and achieve high sensitivity and
selectivity. However, as with all methods, there are limitations with using microdialysis
such as spatial and temporal resolution. Spatial resolution of the dialysis probe is
dependent on the probe’s size. In this set of work, a probe with a length of 2 mm and a
diameter of 240 µm was used. Since the brain is a heterogeneous structure with
discrete anatomical brain regions, the size of the microdialysis probe limits which
regions can be sampled. In order to achieve desirable spatial resolution in a mouse
brain, the microdialysis probe must be small enough to sample a region of interest,
which can be less than 0.5 mm3 (42). In the work throughout this dissertation,
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commercially available probes are used, which limits miniaturizing the probe to examine
specific sub-regions that may be too small to sample from with a commercially available
probe. There would be numerous advantages if microdialysis probes could be further
miniaturized. Currently, the Kennedy group is fabricating sampling probes with of the
following dimensions: 70 μm wide by 85 μm thick by 11 mm long, which would decrease
the amount of tissue damage, and may be suitable for other types of analysis such as
dialysis samples from cells in a culture (43). The second parameter that can be improve
is temporal resolution, which is the time it takes to collect the dialysate sample volume
from the brain and can be adjusted by varying the flow rate of the perfusate. Fast flow
rates can increase the amount of samples collected, but as state previously can deplete
the surroundings of the analyte of interest. Slow flow rates increase sample collection
time, so a delicate balance must be met.
Prior to the microdialysis experiment, mice undergo surgery to implant a guide
cannula targeting the brain region of interest (e.g. CPu or NAc), and upon recovery (3–4
hours later) from surgery a microdialysis probe is implanted and flow of aCSF
commences through syringe pumps. An equilibration period of 12–16 hours occurs
before any sampling takes place. Low flow rates of 0.5–2.0 µL/min are used for
delivering the aCSF to the brain as well as sampling from the brain. Microdialysis allows
samples to be collected from an intact system since the mice are allowed to freely move
within their container (Figure 1.7). Samples are collected every 10–20 min, and are
separated off-line by manual injection of the samples onto the HPLC coupled to
electrochemical detection.
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Figure 1.7 A representative setup for in vivo microdialysis sample collection. After
microdialysis surgery, the mouse is placed in a small cage where he/she has free
access to food and water. The syringe pump is continuously perfusing aCSF through
the microdialysis inlet at a low flow rate (inlet lines are represented by green lines). The
dialysate sample containing the neurotransmitters of interest is collected through the red
lines into a microcentrifuge tube. The inlet and outlet lines are connected to a swivel
that allows the mouse free movement in his/her cage.
1.2.2 Electrochemical detection
The most common method used for distinguishing neurotransmitters from one
another is using HPLC, while the detection method used is typically dependent of the
class of neurotransmitter being analyzed. For example, monoamines are typically
detected with electrochemical detection, while amino acids are detected with
fluorescence or UV, purines with UV, and peptides with MS (44-47). In this dissertation,
the focus lies on monoamine and purine molecules, both of which are known to be
electrochemically active.
Electrochemical detection is based on a molecules ability to be oxidized or
reduced. The electrode materials used for the oxidation/reduction of specific molecules
can be gold, silver, platinum, carbon, or boron-doped diamond (BDD). When using
these electrodes as the detection element with an HPLC, the design of these
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electrochemical cells can be coulometric or amperometric. In a coulometric cell design,
a porous type electrode (which is most commonly carbon) oxidizes 100% of the analyte
since the analyte passes directly through the electrode. With an amperometric cell
design, a disc type electrode is utilized, and only ~10% of the analyte is oxidized
because the solution typically approaches the electrode surface at a 90° angle. For
coulometric cells, the advantage and disadvantage lie in the fact that the electrode
oxidizes 100% of the analyte, and for some samples, complete oxidation of the mobile
phase or matrix passing through the electrochemical cell can create large background
noise making it difficult to quantify the analyte. Since amperometric cells oxidize a small
percentage of the mobile phase matrix, they are less likely to experience large
background noise. Disadvantages with the amperometric cell design lie with the
sensitivity of the detection of an analyte. Depending on the surface material of the
electrode, it is possible that a sample containing a low concentration of the analyte of
interest may not be detected because not enough of the sample matrix comes in
contact with the electrode surface. To mediate this, cross-flow geometries of the cell
design are taken into consideration, and a cross-flow design in which the sample
passes perpendicular across the working electrode is the preferred choice in order to
achieve a uniform potential across the electrode surface.
An advantage of using electrochemical detection to detect neurotransmitters is
that only a few families have electroactive compounds such as the monoamines, amino
acids (through derivatization steps), and purines. Electrochemical detection provides the
sensitivity and selectivity to measure neurotransmitters in relatively low concentrations
ranging in the low pM to high nM. Typically for monoamine analysis, a carbon electrode
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surface is used while for the detection of purine molecules, which generally have high
oxidation potentials (> +1000 mV versus Ag/AgCl reference) a BDD electrode is utilized
(48). Carbon electrodes are not used to detect purine molecules because they often
cannot reach the high potentials to detect the purine molecules, when higher potentials
are used they cause a large increase in the amount of background noise and eventually
oxidize the carbon electrode surface (49). The BDD electrode is a relatively new
electrode material, and is currently only commercially available as an amperometric cell
design (50). Advantages of using the BDD electrode is its higher working potential
range, decreased background noise, electrochemical stability due to diamond surface
coordination, insensitivity to dissolved oxygen, and is less susceptible to electrode
fouling (51, 52).
For separation and detection of monoamines from microdialysis dialysates,
samples were collected and manually injected onto the HPLC and detected using a
coulometric porous carbon electrode or an amperometric BDD electrode versus a
palladium reference. A specific potential was applied to the porous carbon working
electrode relative to the reference electrode, and the resulting current is recorded at the
working electrode. The oxidation current measured is proportional to the analyte
concentration (Equation 1.1). This calculation is mediated by Faraday’s law, which Q is
the number of Coulombs, N is the number of moles, n is the number of electrons, and F
is Faradays constant (9.65 x 104 C/eq).
Q = nFN

(1.1)

Lastly, HPLC with electrochemical detection can also be used to measure tissue
levels of monoamine and purine molecules in the brain. In tissue content analysis,
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brains are dissected into specific anatomic regions and neurotransmitter tissue content
levels are evaluated. The primary difference between microdialysis and tissue content is
that tissue content measures predominantly intracellular neurotransmitter levels, which
can be upwards to 100-fold times higher than extracellular levels. Taken together, both
intra- and extracellular tissue content levels can be measured using HPLC coupled to
electrochemical detection.
1.2.3 Slice fast scan cyclic voltammetry
Fast scan cyclic voltammetry (FSCV) is an electrochemical technique that can be
used in vivo or in vitro to investigate changes in release and uptake of specific
neurotransmitters in the brain (53). In in vitro FSCV (which from this point on will be
referred to as slice FSCV), DA is released from a coronal brain slice by electrical
stimulation. Stimulation is one of the experimental parameters in FSCV that differs from
microdialysis, where no stimulation is required to measure extracellular DA levels.
Although stimulation is required for slice FSCV, it must be made clear that basal DA
levels are not being measured, instead, stimulated DA release. DA detection is
achieved by applying a voltage to a carbon fiber microelectrode. Specifically, a triangle
waveform is applied to the carbon fiber microelectrode with an initial potential of -400
mV. The voltage is quickly ramped up linearly to +1200 mV, and then linearly decreased
back down to -400 mV, versus a Ag/AgCl reference electrode at a scan rate of 400 V/s.
It takes ~9.3 ms to complete the triangle waveform which is repeated every 100 ms. DA
is oxidized to DA-o-quinone at a potential of ~ +600 mV (Figure 1.8), and DA-o-quinone
is reduced to DA at ~ -200 mV during the reverse scan. The oxidation and reduction of
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DA and DA-o-quinone occurring at the electrode surface generates a current, which is
converted to concentration after electrode calibration.

Figure 1.8 Oxidation of DA to DA-o-quinone.
FSCV is considered a complementary technique to microdialysis because it has
excellent temporal resolution with the ability to measure DA release and uptake on a
sub-second time scale. Moreover, the spatial resolution in FSCV is improved compared
to microdialysis since the electrode is smaller with a diameter of 7 µm (versus a 240 µm
diameter with a microdialysis probe) and a length of ~150–200 µm (versus a length of
1–2 mm with a microdialysis probe). As a result of the carbon fiber microelectrodes
small size, the electrode can be inserted into discrete brain regions of interest (e.g.
ability to discriminate between the NAc core and shell) in the brain causing minimal
tissue damage. Typically an electrode without a separation component can measure
one to two analytes at a time (54, 55). Despite the limited number of analytes that can
be detected at the electrode surface, voltammetry provides good chemical selectivity as
the location of the oxidation and reduction peaks on a voltammogram are unique for
each analyte, providing a ‘fingerprint’ to identify the neurotransmitter of interest. An
exception to this ‘fingerprint’ is with respect to DA and NE since they have similar
structures, their oxidation and reduction peaks are very similar. However, NE is not the
predominant neurotransmitter in brain regions with high DA innervation. An issue with
making measurements in slices or in vivo with carbon fiber electrodes, is that the

23
electrode surface is always changing as molecules are being adsorbed to the surface,
which can lead to fouling and an overall decrease in the sensitivity of the electrode. To
circumvent the fouling problems associated with carbon fiber electrodes, BDD
microelectrodes are often employed since they are more resistant to fouling and this is
particularly true with molecules like 5-HT (56-59).
1.2.4 Locomotor activity
Thus far, the methods discussed in detail have focused on measuring the
chemistry of the brain. However, in neuroscience, behavioral monitoring such as
locomotor activity can also provide clues about the chemistry happening in the brain.
Locomotor activity monitoring is a behavioral method where an animal’s activities are
measured in response to a pharmacological stimulation, toxicological insult, or genetic
modification. Locomotor activity monitoring measures a multitude of behaviors and
measurements such as ambulatory distance, stereotypy, and vertical counts. Locomotor
activity places a mouse in a designated chamber or places the mouse’s home cage in
the activity chamber. The activity chamber placed around the animals home cage or
chamber has three sets of bars located outside the cage and are indicated as the x, y,
and z plane (Figure 1.9), where the infrared (IR) beams transmit and receive signal. As
the mouse moves in its home cage, the mouse breaks the IR beam connection from the
transmitter to the receiver and a computer program records these beam breaks as the
amount of movement made by the animal. Ambulatory distance measures the distance
the animal moves in (cm), which is important since it indicates whether or not an animal
is hyper- or hypo-locomotive. Animals that are hyperactive are often thought to have
increased extracellular DA levels, while hypo-locomotive animals are believed to have
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decreased extracellular DA levels (60). Hyperactivity may be a result of pharmacological
stimulation (i.e. psychostimulants such as cocaine or METH) or a genetic alteration (e.g.
DAT knockout mice). Stereotypic behavior measures repetitive movements an animal
makes. Finally, vertical counts measure rearing events, which describe the rodent siting
up on its hind legs. Rearing events are measured in the Z-plane, where the IR beams
are set higher than the X- and Y-beams to properly measure when the animal rears.

Figure 1.9 Diagram of a locomotor activity box.
1.3 Research objectives
1.3.1 Objective 1: Characterization of the dopamine system in female BDNF+/- mice1
The risk of specific neurological diseases and disorders such as Parkinson’s
disease and depression differ between men and women and sex steroid hormones may
account for these differences. Additionally, there is increasing evidence that sex
hormones may be responsible for the regulation of BDNF signaling since BDNF levels
differ between the sexes (61-63). Besides diseases and disorders, sex differences have
also been reported in drug abuse studies as well as the efficacy of therapeutic drugs.

1

This objective includes collaborative work from Madiha Khalid, Ph.D. who performed slice voltammetry
work to further understand release and uptake of the female BDNF+/- mice. These results complement the
findings with microdialysis experiments, providing a better understanding of the changes that were seen
between the genotypes. For more detailed roles, please see contribution section of this dissertation.
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Previous studies done in the Mathews lab determined that male BDNF
heterozygous (BDNF+/-) mice that were approximately three months of age are
hyperdopaminergic in nature (44). The purpose of this study was to determine if young
female BDNF+/- mice (~3 months of age) are also hyperdopaminergic like their male
BDNF+/- counterparts or if this is exclusive to male mice only.
1.3.2 Objective 2: Characterization of the dopamine system in aged BDNF+/- mice2
The purpose of this study was to characterize the DA system in a heterozygous
mouse model in which there was a lifelong reduction of endogenous BDNF protein and
mRNA levels (25, 64). BDNF+/- mice have no gross abnormalities compared to their
wildtype littermates, but BDNF+/- mice are heavier and slightly more aggressive as they
age (65). Previous research in our laboratory has shown that male BDNF+/- mice at ~3
months of age are hyperdopaminergic in nature (44). BDNF+/- mice have increased
extracellular DA levels using microdialysis with a concomitant decrease in release and
uptake of DA as measured by FSCV.
Our hypothesis that this hyperdopaminergia seen in the young mice would
persist throughout the animal’s life, and that these elevated extracellular DA levels lead
to even greater striatal impairments as the animal aged. We hypothesized that these
striatal impairments would cause older mice to be more susceptible to increases in
reactive oxygen species, which is a product of DA metabolism, and ultimately lead to
greater harm to the aging DA neuronal system (66, 67). In this study, both in vivo
microdialysis and slice FSCV were used in combination to characterize the DA system
in 18 month old BDNF+/- mice and their wildtype littermates. This study was the first to
2

This objective includes collaborative work from Francis K. Maina, Ph.D. who performed slice voltammetry
work to further understand release and uptake of the aged BDNF+/- mice. For more detailed role, please
see contribution section of this dissertation.
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use slice FSCV in conjunction with in vivo microdialysis to obtain a comprehensive view
of aging striatal DA dynamics with respect to basal DA concentrations, DA metabolism,
and transporter functionality in aged BDNF+/- mice.
1.3.3 Objective 3: Method development for the simultaneous detection of purine and
monoamine molecules using a boron-doped diamond electrode
Ado and DA are important neurotransmitters in the brain and there is
considerable evidence that they have reciprocal interactions through their receptors.
Unfortunately, there is no reliable and robust electrochemical method available to detect
baseline levels of Ado. Few papers have examined extracellular Ado levels in the brain
because of the lack of reliable methods to quantify Ado. As a result only a few attempts
have been made to measure extracellular or intracellular Ado levels in the rodent brain
(9, 45, 54, 68-71). Those few reports that have measured Ado demonstrate the scant
understanding of extracellular Ado levels in the rat striatum, since the reported
extracellular Ado levels span a range from 50–240 nM (68, 70-72).
To date, the detection of Ado using carbon based electrode cells (glassy or
porous carbon) with HPLC has not been achieved. This is primarily due to the high
oxidation potential of Ado (~ +1500 mV versus a Ag/AgCl reference electrode) and the
surface instability of these carbon-based electrodes. At potentials greater than +1000
mV, the surface of carbon begins to oxidize itself +1000 mV (49). Recently, BDD
electrodes have become commercially available for electrochemical cells for HPLC
analysis (50). BDD electrodes have numerous advantages over the carbon electrodes
such as lower background potentials, wider potential ranges (up to +2000 mV), and
reduced surface fouling (57, 73). These inherent advantages make the BDD electrode
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ideally suited for the detection of Ado using electrochemistry in combination with HPLC.
The goal of this study was to develop a method for the simultaneous detection of DA
and Ado using HPLC with BDD electrochemical detection.
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CHAPTER 2
Materials and Methods
(Portions of the text in this chapter were reprinted or adapted with permission from
Birbeck, J. A., and Mathews, T. A. (2013) Simultaneous Detection of Monoamine and
Purine Molecules Using High-Performance Liquid Chromatography with a Boron-Doped
Diamond Electrode, Anal Chem. Copyright (2013) American Chemical Society, and
submissions to The Neurobiology of Aging, and ACS Chemical Neuroscience.)
The objective of this chapter is to describe experimental details used throughout
this dissertation. The experimental protocols were performed at Wayne State University
and followed Wayne State Universities standards put forth by Occupational Safety and
Health Administration (OSHA) and the Institutional Animal Care and Use Committee
(IACUC).
2.1 Chemicals
Chemicals used for mobile phase, buffers, standards, genotyping, and
anesthesia were of HPLC grade or higher purity, or medical grade, and were purchased
from Sigma Aldrich (St. Louis, MO), Fisher Scientific (Pittsburgh, PA), and EMD
(Gibbstown, NJ). Primers and dNTP’s were obtained from Invitrogen (Carlsbad, CA).
2.2 Animals
Both wildtype (C57BL/6J) and a heterozygous (BDNF+/-) mouse models were
used in these studies. Complete knockout of the BDNF gene (BDNF-/-) is lethal (25) and
therefore, BDNF-/- mice were not bred or used for this study. For breeding, female
C57BL/6J and male BDNF+/- mice were obtained from Jackson Laboratories (Bar
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Harbor, ME, USA). Offspring from the breeding pairs were raised as a colony in-house
(Wayne State University, Detroit, MI) and were housed 3–4 per cage. Animals had
access to food and water ad libitum during their 12-h light/dark cycle. Experiments
conducted on mice between the ages of 3 to 18 months included locomotor activity and
3–5 month old mice (young) or 18 month old mice (aged) for microdialysis and fast scan
cyclic voltammetry (FSCV). All experiments and procedures were designed to minimize
any pain and discomfort for the animals, and were in accordance with the National
Institute of Health Animal guidelines and approved by the Wayne State University
Institutional Animal Care and Use Committee.
2.3 Genotyping
The procedures for the breeding, weaning, and genotypic analysis were
performed by Kelly E. Bosse, Ph.D. and Brooke Neman. Assistance with these
procedures was provided by myself, Katie Logan, Parvejz Khan, Natasha Bohin,
Andrezj Czaja, Christopher Rogalla, Michelle Colombo, and Stephanie Godden.
Three weeks after birth, pups were ear punched for numerical identification, tails
clipped (~3–5 mm), and separated from their parents based on sex into group-housed
vivariums. Tail pieces were immediately placed in a -80 °C freezer until analysis. Each
mouse’s genotype was identified using polymerase chain reaction (PCR) analysis from
the tail DNA collected. Tails were chopped into small pieces and lysed in 500 μL of lysis
buffer (100 mM Tris-base, 1.5 mM NaCl, 5 mM EDTA, 0.2% sodium dodecyl sulfate; pH
to 8.5) and 0.1mg/mL proteinase K. Tubes with tail pieces and lysis buffer were placed
into a 55 °C water bath for 15–24 h to achieve complete protein digestion. After
digestion was completed, the tubes were placed into the centrifuge and spun for 16 min
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at a speed of 20 000 rcf. The tubes were uncapped to release pressure and then placed
back into the centrifuge for another 16 min. After centrifugation was completed, 200 μL
of the supernatant was slowly withdrawn from the top layer of fluid and placed into
newly labeled tubes with 500 μL isopropyl alcohol. The tubes were capped and mixed
by shaking until a white globular precipitate appeared. Tubes were centrifuged again for
another 16 min at 20,000 rcf to spin down the pellet of DNA. This pellet was retained
and washed by adding 500 μL of a 75% ethanol solution and centrifuged again for
another 5 min. The ethanol solution was withdrawn and 6 μL of nanopure water was
added to the DNA pellet in the tube. The tubes were then placed in a desiccator with the
caps open for 15 min. After ethanol evaporated off, 85 μL of tris-EDTA (TE) buffer was
added to each vial of DNA and stored at 4 °C until further analysis was completed. To
approximate how much DNA was present in the sample optical density was determined
by using an ultraviolet spectrometer (UV-1800 Shimadzu, Columbia, MD) set at 260 nm.
A mixture using 4 μL of TE storage buffer and 400 μL of nanopure water was placed
into the cuvette for the blank reference. For the measurement of optical density of the
DNA sample, a mixture of 4 μL of DNA sample was mixed with 400 μL water. This was
repeated for all samples.
For PCR analysis, each DNA sample was split into two PCR tubes. One tube
was labeled for the wildtype primer (5’-CCAGCAGAAAGAGTAGAGGAG-3’) and the
other with the BDNF mutant primer (5’-GGGAACTTCCTGACTAGGGG-3’) each along
with a common primer (5’-ATGAAGAAGTAAACGTCCAC-3’). The master PCR
solutions were prepared for wildtype and BDNF mutant primers. These master mixes
contained the following: 1.28 mM MgCl2, 1.2 μL PCR buffer A (10 mM Tris-HCl, 1.5 mM
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MgCl2, 50 mM KCl; pH 9.0), 0.096 mM of each deoxyribonucleotide triphosphates
(dNTP’s: dATP, dCTP, dGTP, and dTTP), 1 μM of one of the primers (wildtype or BDNF
mutant), and 1 μM NEO primer. Each sample tube then contained 22.8 μL of master
mix, 2 μL of tail DNA sample, and 0.2 μL of taq polymerase. Before tubes were placed
into the thermocycler, a drop of mineral oil was placed into each PCR tube. The cycling
conditions that were used are as followed: 94 °C for 5 min (melting), 58 °C for 1 min
(annealing), 72 °C for 2 min (extension), followed by 35 cycles at 95°C for 1 min, 58 °C
for 1 min, and 72 °C for 2 min. PCR products were then analyzed immediately or stored
in the 4 °C for further analysis.
Analysis of the PCR product was imaged in a 2% agarose gel (6 μL per lane) in
TBE buffer (89 mM Tris-base, 89 mM boric acid, 1mM EDTA, 1mM NaOH; pH 8.0).
PCR products were separated between 125–135 V and visualized using ethidium
bromide (60 μL added to 750 mL of TBE buffer). Wildtype mice were identified by a
single band of genomic DNA in the first column (this column was always designated to
identify the wildtype gene), while BDNF+/- mice were identified from one band of
genomic DNA (active BDNF, 275 base pairs (bp)) in the first column and a second band
of genomic DNA (inactive BDNF, 340 bp) in the ‘BDNF-mutation’ column (Figure 2.1).
The inactive BDNF gene was generated by inserting a neomycin (NEO) resistant
cassette into the active BDNF gene. Addition of the NEO cassette increases the
molecular weight of the BDNF gene, therefore slowing its travel through the gel
electrophoresis (Figure 2.1).
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Figure 2.1 Gel electrophoresis image of genotypic identification for wildtype and
BDNF+/- mice. The first two lanes represent genotypic identification for a wildtype
mouse. The second two lanes identify a BDNF+/- genotype, and the final lane shows the
DNA ladder. For wildtype identification, lane one shows a band at 275 bp, and the
second lane is void of any bands. The third and fourth lanes identify the BDNF+/genotype in which the third lane shows the band at 275 bp representing the active
BDNF gene, and the fourth lane has a band present at 340 bp representing the inactive
BDNF gene. Image courtesy of Stephanie Godden.
2.4 In vivo microdialysis
2.4.1 Surgery
Both male and female mice were used for microdialysis experiments at 3–5
months and 18 months of age. Stereotaxic surgery was performed as follows. Mice
were anesthetized using isoflurane (induction 2–4%; maintenance 0.5–3%). Once the
mice were fully anesthetized, their eyes were protected with sterile ophthalmic ointment.
The top of the mouse’s head was shaved and sterilized using Betadine and alcohol
three times. After confirming that the mouse was completely under surgical plane (which
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is achieved by seeing no reaction from pinching the mouse’s toes), an incision to the
scalp was made and cleaned using a 10% peroxide until bregma was clearly visible on
the skull. Next, the mouse was placed onto the stereotaxic frame, allowing for a burr
hole to be drilled and a CMA/7 guide cannula to be inserted targeting the caudateputamen (CPu). A second burr hole was drilled diagonally across from the cannula on
the contra-lateral hemisphere for insertion of an anchoring screw. Coordinates were
obtained from the mouse atlas to determine CPu placement, and further refined by
experimental determination in mm from bregma: anterior: +1.0, lateral: -1.3, ventral: -2.5
for 18 month mice, and anterior: +0.8, lateral: -1.3, ventral: -2.5 for mice 3–5 months of
age (74). The cannula and screw were anchored, and exposed skull sealed using fast
drying dental cement (Teets, Diamond Springs, CA). After surgery, mice were allowed
to recover for 3 h before the microdialysis probe (2 mm membrane length, 0.24 mm
membrane diameter, Cuprophane, 6 kDa cut-off) was inserted through the guide
cannula. Artificial cerebral spinal fluid (aCSF; composition in mM: 145 NaCl, 3.5 KCl, 2
Na2HPO4, 1.0 CaCl2, 1.2 MgCl2; pH 7.4) was perfused overnight at a flow rate of 0.40
µL/min. Microdialysis experiments commenced the next day at 0700 h, where the first
hour was to allow for equilibration as the flow rate was increased to 1.1 µL/min.
Dialysate samples were collected at 20 min intervals from the freely moving mice.
2.4.2 Microdialysis experiments
The microdialysis technique of zero-net flux was used to determine the basal
extracellular DA levels in the mice (44, 75, 76). Four baseline samples were collected
with aCSF, then using a CMA/402 programmable gradient infusion pump, perfusate
containing 5, 10, and 20 nM DA was delivered through the microdialysis probe for 90
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min each. The DA-containing aCSF solutions contained 200 µM ascorbic acid and the
samples were stored in the -80 °C freezer until use (77). Determination of the DA
concentration entering the probe (DAin) was accomplished by in vitro calibration using
DA-containing aCSF perfused through the dialysis system in absence of a mouse. DAcontaining aCSF was prepared freshly on each day of analysis.
To determine pharmacological DA release with microdialysis, methamphetamine
(METH) was used (Figure 2.2). Before all METH experiments, mice were weighed to
administer the proper dose. Three baseline samples were collected, then mice were
injected intraperitoneally (i.p.) with 1.0 mg/kg dose of METH and dialysate samples
were collected every 20 min for 2 h after the METH injection.

Figure 2.2 Chemical structure of methamphetamine (METH).
DA vesicular release by depolarization of the neuron was induced by perfusing
high potassium aCSF at 60mM (in mM: 60 KCl, 90.5 NaCl, 2.0 Na2HPO4, 1.2 MgCl2, 1.0
CaCl2; pH 7.4) and 120 mM KCl aCSF (in mM: 120 KCl, 30.5 NaCl, 2.0 Na2HPO4, 1.2
MgCl2, 1.0 CaCl2, pH 7.4) was used. In this method, three baseline samples were
collected with regular aCSF, and following the third collected sample, high potassium
aCSF (60 mM or 120 mM KCl) was perfused through the probe for 20 min. After the 20
min perfusion of the high potassium aCSF was completed, the perfusion media was
switched to an infusion only of regular aCSF went through the brain for the last five
subsequent dialysis fractions that were collected.
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2.5 Slice fast scan cyclic voltammetry
All FSCV experiments were conducted by Francis K. Maina, Ph.D. (male and
female mice 18 months of age), and Madiha Khalid, Ph.D. (female mice 3–5 months of
age).
Mice were anesthetized using CO2, sacrificed, and their brains rapidly removed.
The brain was placed into pre-oxygenated (95% O2/5% CO2) cold high sucrose-aCSF
buffer (composition in mM: 180 sucrose, 30 NaCl, 4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2
NaH2PO4, and 10 D-glucose; pH 7.4) for 10 min. A Vibratome® was used to section
each brain into 400-µm thick coronal slices containing the DA rich area of the CPu.
Slices were then placed into oxygenated aCSF (composition in mM: 108 NaCl, 5 KCl, 2
CaCl2, 8.2 MgCl2, 4 NaHCO3, 1 NaH2PO4, 11 D-glucose, 0.4 ascorbic acid; pH = 7.4)
for 1 h before voltammetric analysis. After oxygenation, slices were then placed onto a
custom-made submersion chamber that was kept at a temperature of 32 °C as
oxygenated aCSF flowed over the brain slice at a rate of 1 mL/min.
Carbon fiber microelectrodes approximately 50–200 µm in length were sealed in
a glass capillary in-house for FSCV analysis of DA as previously described (7). The
carbon fiber microelectrode was inserted in the CPu ~75 µm below the surface of the
slice, and the stimulating electrode was placed directly on the slice approximately 100–
200 µm away from the carbon fiber microelectrode. The parameters for detecting DA at
the electrode surface were completed using a triangle waveform where the electrode
potential was initially held at -0.4 V versus an Ag/AgCl reference electrode, ramped up
to +1.2 V, and then returned to -0.4 V at 400 V/s at a frequency of 10 Hz (7, 44, 53). DA
release was evoked every 5 min by a one pulse monophasic stimulation (350 µA, 60 Hz
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with 4 ms pulse width) from the stimulating electrode and stable baseline DA dynamics
of release and uptake were measured for at least 30 min. All electrode and stimulation
parameters were controlled by TH software.
Electrodes were post-calibrated with 3 µM DA and the peak oxidation current
was converted to concentration. The current versus time plots were fit by non-linear
regression using LabVIEW National Instrument software as described by John and
Jones (53). Using a Michaelis-Menton base kinetic model, peak amplitude of release
([DA]p), uptake kinetics (maximum velocity, Vmax), and DA’s ‘apparent’ transporter
affinity (Km) were determined by fitting DA concentration versus FSCV time traces (7).
To evaluate DA’s affinity for DAT, slice FSCV was used with METH, a
competitive inhibitor of the DAT. The competitive inhibition of DA reuptake is reflected
by an increase in DA’s affinity for the DAT, also known as the apparent Km (53).
Equation 2.1 below shows how apparent Km is calculated, where Km is the MichaelisMenton constant and Ki is the inhibition constant. The Ki values are calculated from the
slope of the linear regression line of METH concentration versus apparent Km values
(shown in equation 2.2). The chosen value of Km was 0.16 µM, as previously reported in
literature (53, 78-80).
Apparent Km = Km x (1 + [i]/Ki)

(2.1)

Slope = ∆y/∆x = Km/Ki

(2.2)

After stable DA release was recorded, superfusion of METH began with increasing
concentrations (0.01–10 µM) delivered to the slice every 30 min. Increasing
concentrations of METH were applied to the brain slice since it was previously shown
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that cumulative concentrations of perfused drugs over a slice do not affect DA release
and uptake parameters (53).
2.6 Tissue Content
The majority of DA inside the neuron is sequestered in vesicles to prevent
oxidation or metabolism of the neurotransmitter so it will be readily available upon
receiving an action potential. Intracellular DA levels are approximately 1000-fold higher
in concentration compared to extracellular levels, which are measured by microdialysis.
Briefly, mice were sacrificed by cervical dislocation and their brains were rapidly
removed. The brain regions of the frontal cortex, striatum, nucleus accumbens (NAc),
hippocampus, and midbrain were dissected out, rapidly frozen in liquid nitrogen, and
stored at -80 °C until analysis. On the day of analysis, the tissue was removed from
freezer and allowed to thaw on ice. After being thawed for approximately 20 min, a 250
µL of 0.1 M HClO4 was added to each vial of tissue and was sonicated for 12 to 15 1second pulses at 50% duty, and microtip setting at ~4. Vials were then centrifuged for
10 min at a rate of 12,000 rfc at 4°C. The supernatant was injected onto the HPLC at a
volume of 20 µL. Standard solutions were run to verify peak placement as well to
quantify concentrations of each analyte. Monoamine and purine tissue levels were
represented as ng monoamine or purine per mg of protein. Protein values were
measured using Pierce BCA protein assay kit (Pierce Biotechnology, Rockford, IL).
2.7 HPLC and electrochemical detection
2.7.1 Detection of neurotransmitters using a porous carbon working electrode
Microdialysis or tissue content samples were separated and detected using a
Shimadzu LC-20AD HPLC pump coupled with electrochemical detection, and were
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separated using a reverse phase Phenomenex C18 (2)-HST column (100 mm x 3 mm,
2.5 µm). The neurotransmitters DA and its metabolites, serotonin (5-HT) and its
metabolite, and norepinephrine (NE) were detected using an ESA coulometric cell
Model 5014B microdialysis cell (porous carbon working electrode set at potentials E1 = 150 mV and E2 = +220 mV versus a palladium reference electrode), with a guard cell
(ESA 5020) set at +350 mV placed before the injection loop. Dialysate samples were
eluted isocratically using a mobile phase (composition in mM: 75 NaH2PO4
monohydrate, 1.4–1.8 1-octanesulfonic acid, 0.125 EDTA, 10% acetonitrile, and 0.002%
triethylamine; pH = 3.0 with phosphoric acid (85 wt %) with the flow rate of 0.400
mL/min. The retention times for NE, 3, 4-dihydroxyphenylacetic acid (DOPAC), DA, 5hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), 3-methoxytyromine (3-MT),
and 5-HT were ~3.6, 5.0, 6.5, 10.4, 12.5, 16.3, and 19.4 min, respectively. Analyte peak
areas were determined against known standards by integration using LC Solutions
Shimadzu Software.
2.7.2 Detection of neurotransmitters using a boron-doped diamond working
electrode
Isocratic monoamine and purine separation were completed using a Shimadzu
LC-20A HPLC coupled to an ESA Coulochem III detector. Detection was achieved
using an ESA model 5041 analytical cell with a BDD disc electrode versus a palladium
reference electrode. The column used was a Trinity™ P1, 100 x 3 mm and 3 μm particle
size. Ammonium phosphate mobile phase was composed of the 45 mM ammonium
phosphate, and 4% acetonitrile, pH = 3.00 using phosphoric acid (85 wt %). The mobile
phase was subsequently purged with argon and sonicated. The flow rate was set at
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0.65 mL/min. To determine the proper oxidation potential for the best analysis of DA
and Ado simultaneously, a hydrodynamic voltammogram was constructed and then a
potential was chosen that would sufficiently oxidize both of the analytes, which was set
+840 mV. Approximate analysis time for both DA and Ado was less than 10 min. For
NE, DA metabolites, 5-HT, and its metabolite, total analysis time was 30 min. Analyte
peak areas for monoamine and purine molecules were determined against known
standards and integrated using LC Solutions Shimadzu Software. The retention times
for each molecule that was detected are as follows in min: AMP: 1.5, Ado: 3.1, NE: 4.1,
DOPAC: 5.7, HVA: 6.7, DA: 8.7, 5-HIAA: 11.3, 3-MT: 13.6, and 5-HT: 28.
2.8 Locomotor activity
Mice were separated into singly housed cages 24 h prior to locomotor analysis.
On the day of analysis, mice were transported from the animal facility to the testing
facility, their food and water removed, and their home cage placed into the locomotor
activity static chamber. Mice were allowed to habituate for 1 h to minimize the stress of
transportation and the novel environment. Spontaneous locomotor activity was recorded
using 3 sets of 16-beam infrared (IR) emitter-detector arrays (Med Associates, St.
Albans, VT) (81). Interruptions of IR beams resulted in an analog signal being recorded
by automated activity software (Open Field Activity Software [SOF-811], Med
Associates, St. Albans, VT). The locomotor activity system quantified total beam breaks
in both the vertical and horizontal planes, specifically encoding measures of distance
traveled (cm; calculated from number of breaks of adjacent beams), ambulatory time
(s), and number of rears. Baseline ambulatory distance was measured for a total of 2 h
and binned into 10 min periods.
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To determine locomotor stimulation following METH administration, baseline
activity was determined for the first hour then mice were then injected i.p. with saline
(1.0 mL) and locomotor activity was collected for a second hour. Mice were then
injected with METH (1.0 mg/kg, i.p.) and locomotor activity was collected for an
additional 2 h. Total analysis time was 4 h.
2.9 Statistical analysis
Neurochemical data analysis was performed using GraphPad Prism® software.
Values were reported as mean ± standard error of mean (SEM) with the criterion for
statistical significance set to P < 0.05. For zero-net flux analysis linear regression
analysis, the x-axis represents the concentration of DA being perfused into the probe
determined by in vitro analysis (DAin), and the y-axis represents the difference of DAout,
which is defined as the concentration of DA in the dialysate sample from DAin (75). The
point at which the regression line crosses the x-axis is known as DAext and indicates the
basal extracellular concentration of DA. The slope of the regression line was used to
determine the in vivo recovery of DA (Ed, dialysate extraction fraction) (82). Student’s ttest was used to determine if a significant difference existed between the genotypes
with respect to DAext, extracellular metabolite concentrations, metabolite/DA ratio, and
tissue content. For analysis of high potassium and METH microdialysis studies, two-way
analysis of variance (ANOVA) analysis was used.
Release and uptake, as determined by FSCV, were analyzed using the
Michaelis-Menten kinetic based model which determines changes in [DA]p, Vmax, and
apparent Km (53, 79, 83). To determine differences in electrically stimulated DA uptake
and release between genotypes a two-tailed Student’s t-test was used.
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Locomotor activity, baseline and METH-induced, were analyzed (IBM SPSS®
Statistics for Windows) using a 2 x 3 x 12 three-way, repeated measures analysis of
variance (ANOVA) with genotype (wildtype or BDNF+/-) as the between-subjects factors,
and month (12, 15, or 18) and the 12 time blocks as nested within-subjects factors.
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CHAPTER 3
Potentiated striatal dopamine release leads to female BDNF+/- mice
hyperdopaminergia
(Portions of the text in this chapter were adapted from the submission to ACS Chemical
Neuroscience)
3.1 Introduction
Risk of developing neurological diseases and disorders are different among men
and women. An example of this is seen with regards to Parkinson’s disease, a disease
characterized by dopamine (DA) neuron degeneration in the striatum, which men are
~1.5 time more likely to develop the disease than women (35). In the case of depressive
disorders, which include both the dopaminergic and serotonergic pathways, women are
two times more prone to developing them than men (84). To better understand the
gender differences in these neurological conditions, research has focused on the
molecules implicated in these conditions, such as neurotransmitters DA and serotonin,
as well as the neurotrophins that protect the neurons, such as brain-derived
neurotrophic factor (BDNF) (37, 85, 86).
To better understand the sex-differences in disease risk and progression,
gonadal hormones such as estrogen and testosterone have been investigated in
addition to other associated molecules such as DA and BDNF. In ovariectomized rats, a
physiological dose of estrogen increased striatal extracellular DA concentrations and
tyrosine hydroxylase activity (38). Furthermore, estrogen was shown to act upon and
stimulate similar downstream second messengers, ERK1 and ERK2, in a similar
manner as BDNF in cortical explant cultures (87). Additionally, female rats showed an
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increase in depression vulnerability in comparison to males rats when their BDNF levels
were at their lowest, which was shown to correlate to when estrogen levels are at their
highest (36, 88, 89).
Sex differences are also observed in neurological disorders, such as addiction, in
which females and males respond differently to drugs of abuse. For example, women
are more likely to start using illicit drugs sooner than men, and consume greater
quantities of these drugs (90, 91), while men are more likely to die from an overdose
versus women (92). Taken together, these observations in animal and clinical studies,
have led researchers to hypothesize that females may be protected from the neurotoxic
effects of drugs because of their naturally higher levels of estrogen (93-95).
Numerous studies have elucidated the importance of BDNF in maintaining the
function and survival of DA neurons in the striatum (26, 28-30). To better understand
BDNF’s endogenous role throughout the brain and body, genetically modified
heterozygous (BDNF+/-) mice developed by Ernfors and colleagues were used (25).
With respect to DA neurochemistry, male BDNF+/- mice have increased extracellular and
intracellular DA levels, (29, 44, 96), which were not associated with alterations in the DA
transporter. The objective of this study was to determine if these striatal DA alterations
are present in female BDNF+/- mice. Using the complementary techniques of in vivo
microdialysis and slice fast scan cyclic voltammetry (FSCV), DA dynamics were
investigated in female wildtype and BDNF+/- mice.
3.2 Results and Discussion
3.2.1 Elevated basal striatal DA levels in female BDNF+/- mice
Female BDNF+/- mice, 3–5 months of age, were used to determine the effect of
reduced BDNF protein and mRNA on the striatal dopaminergic system compared to
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female wildtype littermates. Using the technique of microdialysis, the uncorrected
extracellular DA levels (averages of 3–4 baseline samples per mouse) in the caudate
putamen (CPu) of wildtype and BDNF+/- mice showed no difference between genotypes
(Figure 1 inset; wildtype mice: 3.5 ± 0.5 nM, n = 7 and BDNF+/- mice: 3.8 ± 0.5 nM, n =
10, P = 0.62). When extracellular DA levels were evaluated in-depth using the in vivo
microdialysis method of zero-net flux, basal extracellular DA ([DA]ext) levels and
extraction fraction (Ed) were determined for each genotype (Figure 3.1). An ~2-fold
increase in [DA]ext was observed in the female BDNF+/- compared to their wildtype
littermates (Figure 3.1, wildtype mice: 8.2 ± 1.6 nM, n = 7 and BDNF+/- mice: 15.0 ± 1.8
nM, n = 10, P < 0.05). The basal DA levels in female BDNF+/- mice are similar to male
BDNF+/- mice of the same age such that both sexes have an ~2-fold increase in striatal
DA levels compared to their wildtype littermates (44). To determine if this difference in
basal DA levels is due to alterations in the DA transporter (DAT), Ed (slope of the line)
was calculated. Ed is a measure of DAT mediated uptake (82), and was not different
between female BDNF+/- (0.30 ± 0.02, n = 10) and female wildtype (0.31 ± 0.04, n = 7, P
= 0.47) mice (Figure 3.1, inset). This is in agreement with other’s that show striatal DAT
density and activity is unchanged in BDNF+/- mice (29, 64). Although female BDNF+/mice have elevated extracellular DA levels, our zero-net flux results suggest this is not a
result of striatal DAT alterations.

45

Figure 3.1 Extracellular DA concentration as measured by zero-net flux. Inset shows
uncorrected DA extracellular levels, [DA]ext, and the extraction fraction, Ed. Significance
was seen between the wildtype (WT) and BDNF+/- mice with regards to [DA]ext (WT: 8.2
± 1.6 nM and BDNF+/-: 15.0 ± 1.8 nM, *P < 0.05). No difference was observed in the
uncorrected DA levels or Ed. N values are 7–10 mice per genotype.
3.2.2 DA metabolites are not different across genotypes
Inactivation of extracellular DA is regulated through the enzymatic breakdown of
DA by the enzymes monoamine oxidase (MAO) to form 3,4-dihydroxypheylacetic acid
(DOPAC) and catechol-o-methyl transferase (COMT) to form the metabolite 3methyoxytyramine (3-MT). The DA metabolite 3-MT is transient in the brain and is not
found in sufficiently high concentrations for detection, and therefore only DOPAC and
HVA were measured. For both DOPAC and HVA, 3–4 microdialysis samples were
collected and analyzed. Both the female wildtype and BDNF+/- mice showed similarities
in their extracellular metabolite concentrations of DOPAC (wildtype mice: 378 ± 69 nM,
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n = 8, and BDNF+/- mice: 421 ± 110 nM, n = 7, P = 0.73, Figure 3.2) and HVA (wildtype
mice: 610 ± 52 nM, n = 7, and BDNF+/- mice: 672 ± 120 nM, n = 5, P = 0.61, Figure 3.2).
Metabolite levels are not different between the genotypes suggesting that the increase
in extracellular DA is not caused by alterations in DA metabolism. Our DA metabolite
data is consistent with what has been previously observed using male wildtype and
BDNF+/- mice (44).

Figure 3.2 Extracellular DA metabolite levels as measured by microdialysis. No
difference is observed between the genotypes for metabolites DOPAC or HVA. Data
represented as mean ± SEM, and n values are 5–9 mice per genotype.
3.2.3 Slice FSCV: DA release is elevated in the female BDNF+/- mice
All slice voltammetry experiments and analysis was conducted by Madiha Khalid, Ph.D.
Presynaptic DA release ([DA]p) and DA reuptake (Vmax) were examined to
determine if these parameters were altered in female BDNF+/- mice, which may
contribute to the elevation of extracellular striatal DA levels. Using 400 µm thick brain
slices that contain the CPu of the mouse, a bi-polar stimulating electrode was used to
evoke electrically stimulated DA release, which was subsequently measured using a
carbon-fiber microelectrode. The female BDNF+/- mice revealed increased DA release
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per pulse ([DA]p = 1.4 ± 0.2 µM, n = 8) compared to their wildtype counterparts ([DA]p =
0.70 ± 0.6 µM, n = 6, P < 0.05, Figure 3.3A), but there was no difference between the
genotypes with respect to the rate of DA uptake (Vmax values wildtype: 3.2 ± 0.2 µM/s, n
= 6, and BDNF+/-: 3.4 ± 0.3 µM/s, n = 8, P = 0.54; Figure 3.3B).
The increase in stimulated DA release corroborates with our zero-net flux
findings, where higher basal DA levels in the striatum of the female BDNF+/- mice were
observed compared to the wildtype female mice. Interestingly, when the slice FSCV
results from the sexes are compared, the evoked DA release from the female BDNF+/mice is potentiated compared to male BDNF+/- mice (44). Unlike the female BDNF+/mice, male BDNF+/- mice have a decrease in both DA release and uptake in comparison
to their wildtype littermates (44). Thus low endogenous BDNF levels appear to have a
greater impact on influencing stimulated DA release in the female BDNF+/- mice
compared to their male counterparts.

Figure 3.3 DA release and uptake in the CPu of female mice as measured by slice fast
scan cyclic voltammetry. A) Average DA release per pulse [DA]p in µM, and B) average
DA uptake rates, Vmax, in µM/s. Data represented as mean ± SEM.’s and n values are
6–8 per genotype, **P < 0.01.
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3.2.4 Microdialysis stimulated DA release is potentiated in female BDNF+/- mice
To determine vesicular DA release, in vivo microdialysis was used to infuse a
high concentration of potassium (K+) to induce stimulation at the striatal neuronal
terminals. In these experiments, three baseline samples were collected after which high
K+ (60 mM KCl) containing artificial cerebral spinal fluid (aCSF) was perfused through
the microdialysis probe for one 20 minute sample, followed by aCSF for the remainder
of the experiment (Figure 3.4). The 60 mM K+ aCSF elevated extracellular DA levels by
at least 5-fold in both genotypes. There appears to be a trend towards higher DA levels
in the female BDNF+/- mice versus their wildtype littermates, but striatal extracellular DA
levels were not significant by a two-way ANOVA. Post-hoc analysis revealed a
significant potentiation in DA levels in female BDNF+/- mice 20 min after high K+
perfusion versus wildtype mice (Bonferroni posttest, P < 0.01).

Figure 3.4 High potassium (K+) stimulated DA release from the CPu. Three 20 minute
baseline samples were collected after which one 20-min perfusion of 60 mM K+ aCSF
was administered through the dialysis probe directly into the CPu. Data are mean ±
SEM.’s show change in extracellular DA concentration upon K+ infusion. N values are 6
mice per genotype, **P < 0.01 (Bonferroni posttest).
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Overall, both in vivo microdialysis and slice FSCV demonstrate that stimulated
DA release in the CPu of female BDNF+/- mice was potentiated compared to female
wildtype mice. When comparing the BDNF+/- female mice to their male counterparts, a
divergence in their response to high K+ stimulation with 60 mM KCl aCSF was
observed, where there was a decrease or no effect on DA release in the male BDNF+/mice compared to their wildtype littermates (44, 64). This potentiation in stimulated DA
release in females could be supported by the presence of estrogen, since estrogen
pretreatment on the striatum significantly enhances DA extracellular levels, while
testosterone treatment has no effect (97-99). However, to clearly delineate the roles of
these sex hormones on striatal DA release dynamics, it is imperative that future studies
evaluate these interactions to assist our understanding of this estrogen and its complex
effects on neurotransmitter systems. Overall, both microdialysis and slice FSCV data
suggests that female BDNF+/- mice release more DA when the system is stimulated
either via high K+ or electrical stimulation. If the striatal DA system is hyper-responsive
then these results could possibly explain why the female BDNF+/- mice have elevated
extracellular DA levels without a difference in DAT activity.
3.2.5 Methamphetamine-stimulated DA release via microdialysis is potentiated in
the female BDNF+/- mice
Methamphetamine (METH), a substrate for the DAT, causes a conformational
change to the DAT in which DA is primarily released from its transporter instead of
being re-uptaken. Furthermore, METH disrupts the vesicular monoamine transporter
(VMAT)-proton pump causing DA to be displaced from the vesicle. In clinical and animal
models, high doses of METH or repeated doses in a single day of METH are neurotoxic
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to the DA system by perturbing the central DA signaling (100-103). METH induced
elevations in non-sequestered intracellular DA levels is thought to lead to an
environment in where there is a greater probability of DA oxidation leading to the
eventual formation of reactive oxygen species (ROS) in the cytosol, and ultimately
nerve terminal damage (104, 105). However, low doses of METH, as used in this study,
can be locomotor activating, and research has shown that increases in locomotor
activity can be indicative of increases in extracellular DA levels (106).
METH was used to investigate BDNF’s role with respect to gender upon
pharmacological manipulation of the DAT. Female wildtype and BDNF+/- mice were
injected with a low dose of METH (1 mg/kg, intraperitoneally (i.p.)) which is known to
activate locomotor activity (107, 108). Microdialysis samples were collected in 20 minute
fractions for 3 hours after injection (Figure 3.5). Two-way ANOVA analysis revealed a
main effect of genotype (F1, 178 = 17.7, P < 0.001), treatment (F11, 178 = 20.7, P < 0.001),
and a significant interaction effect (F11, 178 = 1.91, P < 0.05) demonstrating that METH
induced genotype-dependent elevations in extracellular DA levels. The maximal METHinduced response for both genotypes was 40 min after injection. A post-hoc test
indicated that stimulated DA release was significantly potentiated at 100 and at 120 min
(P < 0.01, and P < 0.05, respectively) in female BDNF+/- mice compared to their wildtype
controls (Figure 3.5).
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Figure 3.5 Methamphetamine (METH) stimulated striatal DA release. METH (1 mg/kg,
i.p.) was administered at the end of the third baseline sample and DA levels were
measured for the next 180 min. Data are represented as percent baseline of
extracellular DA. N values are 7–10 per genotype. Two-way ANOVA indicates main
effect of time and genotype, ***P < 0.001. *P < 0.05 and **P < 0.01, Bonferroni posttest.
The balance between gonadal sex hormones, neurotransmitters and other
neuromodulators like BDNF influence the susceptibility of sex differences in different
neurological diseases/disorders. For example with drugs of abuse, often individuals
experiment with drugs of abuse to self-medicate stress, anxiety, and depression (109).
Women are more susceptible to experiencing depression and anxiety disorders, and a
leading hypothesis is the BDNF plays a critical role in regulating mood (36, 110). These
results disagree with previous work done by Dluzen, in which he suggested that the
reduction in BDNF in the heterozygous mice might protect the heterozygous mice from
the deleterious effects of METH because of reduced re-uptake of DA (93). However,
this appears not the case with our finding since the female BDNF+/- mice do not have a
reduction in DA uptake from the DAT when compared to their wildtype counterparts.
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Therefore, our results suggest that BDNF is important for regulation of DA dynamics in
the striatum, and there is a considerable difference on how low BDNF levels influence
striatal DA dynamics depending on the sex. These results further suggest that
neuromodulators like BDNF and sex hormones combined have a powerful impact on
striatal DA dynamics, where female BDNF+/- mice appear to be altered only with respect
to DA release while male BDNF+/- mice have both release and uptake altered. These
sex differences may be of particular interest when it comes to the administration of
pharmacological agents that are meant to relieve anxiety or depression.
3.5 Conclusions
The increase in extracellular DA as measured by the microdialysis method of
zero-net flux suggests that female BDNF+/- mice are hyperdopaminergic like their male
counterparts. This hyperdopaminergia is not a result of alterations in DAT functionality
or DA metabolism, as they were consistent between the genotypes. However, there
appears to be a difference in how the sexes reach a hyperdopaminergic state. Female
BDNF+/- mice have potentiated DA release as measured in three-independent
experiments: slice FSCV, high K+ microdialysis, and microdialysis following a low-dose
of the psychostimulant METH. Overall, these DA release findings suggest that there is a
complex relationship between BDNF, the sex hormones, and how they influence striatal
DA release together. The potentiation in extracellular DA levels in female BDNF+/- mice
appears to be due to an increase in DA release, while the elevated extracellular DA
levels in male BDNF+/- mice is hypothesized to be a result of compensatory mechanism
between their release and uptake. Estrogen may be responsible for these DA changes,
since it has been hypothesized that estrogen acts directly on the DA terminals
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increasing DA release by down-regulating DA D2 receptors (111). Taken together, when
comparing these current findings with regards to differences in DA dynamics with
female BDNF+/- mice with respect to their male counterparts (44), it appears that there is
a more intricate relationship at work between BDNF and sex hormones.
3.4 Materials and Methods
3.4.1 Mice
Female C57/Bl6J (wildtype) and BDNF+/- (heterozygote) mice between 3–5
months of age were used in this study. Mice were bred in house from breeder pairs of
female wildtype and male BDNF+/- mice obtained from Jackson Laboratories (Bar
Harbor, ME, USA). Mice were weaned 21 days after birth, tail clipped, and ear punched
for identification purposes. Genotyping was done by PCR reaction using DNA from the
tail clippings in order to identify the wildtype mice from the heterozygotes as there are
no phenotypic differences observed in these mice (44). Mice were group housed as 3–6
animals per cage. All procedures and experiments were designed to minimize any pain
and/or discomfort to the animals and were in accordance with the National Institute of
Health Animal guidelines and approved by the Wayne State University Institutional
Animal Care and Use Committee.
3.4.2 Microdialysis: Surgery and Experimentation
Female mice were used for all experiments and were not examined for their
estrous cycle phase when microdialysis and voltammetry experiments were conducted.
The estrous cycle was not taken into account for any experimental conditions because
as Walker and Yu showed DA release and uptake is independent of estrous state and
does not change in C57BL6/J mice (112-114). Mice were anesthetized using isoflurane
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and a burr hole was drilled from coordinates relative to the bregma (anterior: +0.8,
lateral: -1.3, ventral: -2.5) (44, 74). A CMA/7 guide cannula was inserted into the burr
hole that was drilled into the skull targeting the CPu. The guide cannula was affixed to
the skull using dental cement and the mice were allowed to recover for 3–4 hours after
surgery before a microdialysis probe (2 mm membrane length, 0.24 mm membrane
diameter, Cuprophane, 6 kDa cut-off) was inserted through the guide cannula. Next,
aCSF (composition in mM: 145 NaCl, 3.5 KCl, 2 Na2HPO4, 1.0 CaCl2, 1.2 MgCl2; pH
7.4) was perfused at a flow rate of 0.4 µL/min overnight. The next morning, flow rate
was increased to 1.1 µL/min and equilibrated for one hour before experimentation
began. Dialysate samples were collected in 20 min fractions for a total sample volume
of 22 µL from the freely moving mice.
To determine basal extracellular levels of DA, the method of zero-net flux was
employed as previously described (44, 75, 76). Four 20 min baseline samples were
collected, and aCSF perfusate containing 5, 10, and 20 nM DA was perfused into the
striatum using a CMA/402 programmable gradient infusion pump. Collected dialysate
samples were stored in a -80 °C freezer until analysis (77).
For the zero-net flux experiments, the plotted x-axis represents the DA
concentration perfused into the probe, DAin (determined by in vitro analysis), and the yaxis is plotted as the difference in concentration perfused in from the concentration of
DA collected from the probe (DAout). The point at which this linear regression line
crosses the x-axis is known at the DAext, which corresponds to the basal extracellular
DA concentration DAin (75). The slope of the regression line, Ed, was used to determine
the in vivo recovery of DA (82).
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DA vesicular release by depolarization of the neuron, a method which requires
perfusion of high K+ aCSF at 60 mM (in mM: 60 KCl, 90.5 NaCl, 2.0 Na2HPO4, 1.2
MgCl2, 1.0 CaCl2; pH 7.4) was used. In this method, three baseline samples were
collected with standard aCSF, and following the third collected sample, high K+ aCSF
was perfused through the probe for 20 min. After the 20 min perfusion of the high K+
aCSF was completed, the pump was switched so that only standard aCSF was
perfused for the last five subsequent dialysis fractions that were collected.
Pharmacological release of extracellular DA was achieved by using METH. Mice
were weighed before analysis in order to calculate proper doses for intraperitoneal (i.p)
injection. Three baseline samples were collected before mice were injected with a 1
mg/kg dose of METH, and samples were collected every 20 min for another 3 h after
injection.
3.4.3 Slice fast scan cyclic voltammetry
All slice voltammetry experiments and analysis was conducted by Madiha Khalid, Ph.D.
Slice fast scan cyclic voltammetry experiments are the same as previously
described (44, 115). Briefly, female mice were asphyxiated using CO2 and immediately
sacrificed, after which their brains were removed and placed into pre-oxygenated (95%
O2/5% CO2) cold high sucrose aCSF buffer (in mM: 180 sucrose, 30 NaCl, 4.5 KCl, 1
MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10 D-glucose; pH 7.4) for 10 min. The brain was
sectioned into 400 µm thick coronal slices, and the slices containing the CPu were
placed into an oxygenating aCSF (in mM: 108 NaCl, 5 KCl, 2 CaCl2, 8.2 MgCl2, 4
NaHCO3, 1 NaH2PO4, 11 D-glucose, 0.4 ascorbic acid; pH = 7.4) chamber at room
temperature. After a 1 h equilibration period, the slices were placed onto a custom-
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made submersion chamber kept at a temperature of 32 °C and the oxygenated aCSF
was perfused over the brain slices at 1 mL/min for the remainder of the experiment.
Carbon fiber microelectrodes (50–200 µm in length) were made in-house for
FSCV analysis of DA as previously described (115, 116). The microelectrode were
placed in the CPu ~75 µm into the tissue of the slice. The stimulating electrode was
placed ~100–200 µm away from the carbon microelectrode. A triangle waveform was
used to detect DA from the surface of the electrode by applying a potential starting at 0.4 V versus a Ag/AgCl reference electrode, ramping it up to +1.2 V, then bringing it
back down to -0.4 V at a frequency of 10 Hz and scan rate of 400 V/s (44, 115, 116).
Stimulation was applied every 5 min and subsequent DA release and uptake were
recorded until three stable baseline readings were achieved. All of the electrode and
stimulation parameters were controlled by TH software. Post-calibration of electrodes
were completed after each experiment using a 3 µM DA solution so that peak oxidation
could be converted to concentration. Current versus time plots were fitted by non-linear
regression as described by John and Jones, using LabVIEW National Instrument
software (53). DA release, [DA]p, and uptake, Vmax, were determined using MichaelisMenten based kinetics by fitting DA concentration versus time traces (7, 116).
3.4.4 Statistical Analysis
All analysis for microdialysis experiments were performed using GraphPad
Prism® software. Values are reported as mean ± standard error of the mean (SEM) with
statistical significance set at P < 0.05. Student’s t-test was used to determine
significance between genotypes with respect to uncorrected DA, DAext, and metabolites
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while genotypic analysis for high K+ and METH were compared using two-way ANOVA
analysis.
FSCV results of DA release and uptake were analyzed using Michaelis-Menten
kinetic model, which measures the change in [DA]p and Vmax (53, 79, 83). Student’s ttests were used to determine change in electrically stimulated DA release and uptake
rates between the genotypes.
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CHAPTER 4
Normalized striatal dopamine dynamics in aged BDNF deficient mice
(Portions of the text in this chapter were adapted from the submission to The
Neurobiology of Aging)
4.1 Introduction
Aging is a natural process that all living organisms experience. Though the rate
of aging is different across species, changes in the biological processes during aging
are similar. One of the main hallmarks of aging is the slowing of motor movements and
coordination typically associated with striatal dopamine function (117). Over a lifetime,
degradation of nigral-striatal neurons occurs at a rate up to ~35% and correlates with an
~60% decrease in dopamine (DA) levels in humans (5, 118, 119). Specifically, aging
causes substantial changes to the striatal DA system in these ways: 1) decreases in DA
levels (5, 120), 2) decreases in D2 receptors and the DA transporter (DAT) (121, 122),
3) decreases in tyrosine hydroxylase (TH) concentrations and neurons (123, 124), and
4) increases in free radicals by monoamine oxidase (MAO) during DA metabolism (66,
125). Severe striatal DA deficits contribute to specific neurological diseases or disorders
associated with age such as Parkinson’s and Huntington’s disease (3, 119, 126).
However, it is naïve to suggest that a single neurotransmitter or neuromodulator system
is involved with these age-related neurological diseases. Recent evidence indicates
there is also an associated decrease in levels of brain-derived neurotrophic factor
(BDNF) along with DA deficits (3, 127, 128).
BDNF is a neurotrophic factor responsible for neuronal maintenance, survival,
and growth. BDNF is synthesized in the substantia nigra (SN) and the cortical pyramidal
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neurons and is anterogradely transported to the medium spiny neurons (MSNs) (31,
129, 130). Upon synaptic stimulation, BDNF binds to its receptor tyrosine kinase
receptor B (TrkB) expressed on striatal MSNs (24). When BDNF is applied exogenously
to mouse striatal slices or rat striatal neuronal cultures, BDNF increases DA release and
survival of DA neurons, respectively (28, 44). During the normal aging process, protein
levels of BDNF in the striatum have been shown to decrease in both rats and mice
(131), as well as a concomitant decreases in TrkB and TH messenger ribonucleic acid
(mRNA) levels in the striatum (64, 123). Furthermore, in animal models mimicking
Parkinson’s disease, dopaminergic neuronal cultures treated with BDNF before the
application of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) were protected
from the neurotoxic effects of its metabolite 1-methyl-4-phenylpyridinium (MPP+) (28).
Additionally, results from various studies to date suggest that there is a reciprocal
relationship between DA and BDNF.
With the relationship between DA and BDNF becoming ever more apparent, the
purpose of this study was to characterize the DA system in a heterozygous mouse
model in which there was a lifelong reduction of endogenous BDNF protein and mRNA
levels (25, 64). BDNF+/- mice have no gross abnormalities compared to their wildtype
littermates, but are heavier and slightly more aggressive as they age (65). Previous
research in our laboratory has shown that BDNF+/- mice at ~3 months of age are
hyperdopaminergic by nature (44). Our hypothesis was that this hyperdopaminergia
would persist throughout the animal’s life, and that these elevated extracellular DA
levels would lead to even greater striatal impairments. These striatal impairments are
thought to be caused by older mice being more susceptible to increases in reactive
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oxygen species (ROS), a product of DA metabolism and harmful to an aging neuronal
system (66, 67). In this study, both in vivo microdialysis and slice fast scan cyclic
voltammetry (FSCV) were used in combination to characterize the DA system in 18
month old BDNF+/- mice and their wildtype littermates. This study was the first to use
slice FSCV in conjunction with in vivo microdialysis to obtain a comprehensive view of
aging striatal DA dynamics with respect to basal DA concentrations, DA metabolism,
and transporter functionality in aged BDNF+/- mice.
4.2 Methods
4.2.1 Animals
A heterozygous (BDNF+/-) mouse model was used in this present study because
a complete knockout of BDNF (BDNF-/-) in mice is lethal (25). Female C57BL/6J and
male BDNF+/- mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA).
Offspring from these mice were raised as a colony in-house (Wayne State University,
Detroit, MI) and were housed 3–4 per cage. Animals had access to food and water ad
libitum during their 12-h light/dark cycle. Each mouse’s genotype was identified using
PCR analysis of tail DNA and performed as previously described (132). Experiments
conducted on mice between the ages of 12 to 18 months included locomotor activity
and microdialysis at 18 months, and voltammetry on 3–5 month old mice (young) or 18
month old mice (aged). All experiments and procedures were designed to minimize any
pain and discomfort for the animals, and were in accordance with the National Institute
of Health Animal guidelines and approved by the Wayne State University Institutional
Animal Care and Use Committee.
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4.2.2 Microdialysis
Both aged male and female mice were used for microdialysis experiments.
Stereotaxic surgery was performed as previously described (44) except that mice at 18
months were anesthetized using isoflurane (induction 2-4%; maintenance 0.5-3%). A
burr whole was drilled and a CMA/7 guide cannula was inserted targeting the caudateputamen (CPu). Coordinates were obtained from the mouse atlas and experimental
determination (in mm from Bregma: Anterior: +1.0, Lateral: -1.3, Ventral: -2.5) (74). After
surgery, mice were allowed to recover for 3 h before the microdialysis probe (2 mm
membrane length, 0.24 mm membrane diameter, Cuprophane, 6 kDa cut-off) was
inserted through the guide cannula. Artificial cerebral spinal fluid (aCSF; composition in
mM: 145 NaCl, 3.5 KCl, 2 Na2HPO4, 1.0 CaCl2, 1.2 MgCl2; pH 7.4) was perfused
overnight at a flow rate of 0.40 µL/min. Microdialysis experiments were started the next
day at 0800 h and at least 1 h before the flow rate was increased to 1.1 µL/min to allow
for equilibration. Dialysate samples were collected at 20 min intervals from the freely
moving mice.
The microdialysis technique of zero-net flux was used to determine the basal
extracellular DA levels in the 18 month old mice as previously described (44, 75, 76).
Four baselines samples were collected with aCSF, then using a CMA/402
programmable gradient infusion pump, perfusate containing 5, 10, and 20 nM DA was
delivered through the microdialysis probe for 90 min each. The DA-containing aCSF
solutions contained 200 µM ascorbic acid and the samples were stored at -80 °C until
use (77). Determination of the DA concentration entering the probe (DAin) was
accomplished by in vitro calibration using DA-containing aCSF perfused through the
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dialysis system in absence of a mouse. DA-containing aCSF was prepared freshly on
each day of analysis. To determine pharmacological DA release using microdialysis,
methamphetamine (METH) was used. Before all METH experiments, mice were
weighed to achieve proper dosing. At least three baseline samples were collected, then
mice were injected intraperitoneally (i.p.) with 1.0 mg/kg dose of METH and dialysate
samples were collected for 2 h after the METH injection.
Samples were separated and detected using a Shimadzu LC-20AD HPLC pump
coupled with electrochemical detection, and were separated using a reverse phase
Phenomenex C18 (2)-HST column (100 mm x 3 mm, 2.5 µm). DA was detected using an
ESA coulometric cell Model 5014B microdialysis cell (potential E1 = -150 mV and E2 =
+220 mV versus a palladium reference electrode), with a guard cell (ESA 5020), set at
+350 mV, placed before the injection loop. Dialysate samples were eluted isocratically
using a mobile phase (composition in mM: 75 NaH2PO4 monohydrate, 1.4–1.8 1octanesulfonic acid, 0.125 EDTA, 10% acetonitrile, and 0.002% triethylamine; pH = 3.0,
adjusted with 85% phosphoric acid) with the flow rate of 0.400 mL/min. The retention
times for 3, 4-dihydroxyphenylacetic acid (DOPAC), DA, and homovanillic acid (HVA)
were ~5, 6.5, and 12.5 min, respectively. Analyte peak areas were determined against
known standards by integration using LC Solutions Shimadzu Software. After dialysis
experiments were completed, mice were sacrificed, and brains were sectioned for
histological confirmation of probe placement.
4.2.3 Slice voltammetry
Slice voltammetry experiments and analysis was conducted by Francis K. Maina, Ph.D.
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Slice voltammetry experiments were similar to those described in Bosse et al.,
(44). Briefly, mice were anesthetized with CO2 and their brains were rapidly removed,
and were placed into pre-oxygenated (95% O2/5% CO2) cold high sucrose-aCSF buffer
(composition in mM: 180 sucrose, 30 NaCl, 4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2
NaH2PO4, and 10 D-glucose; pH 7.4) for 10 min. A Vibratome® was used to section
each brain into 400 µm thick coronal slices containing DA rich areas of the CPu and
nucleus accumbens (NAc). Slices were then placed into oxygenated aCSF (composition
in mM: 108 NaCl, 5 KCl, 2 CaCl2, 8.2 MgCl2, 4 NaHCO3, 1 NaH2PO4, 11 D-glucose, 0.4
ascorbic acid; pH = 7.4) for 1 h before being placed onto a custom-made submersion
chamber for voltammetric analysis. The submersion chamber was kept at a temperature
of 32 °C as oxygenated aCSF flowed at a rate of 1 mL/min.
Carbon fiber microelectrodes approximately 50–200 µm in length were sealed in
a glass capillary in-house for FSCV analysis of DA as previously described (7). The
carbon fiber microelectrode was placed in the CPu ~75 µm below the surface of the
slice in the CPu, and the stimulating electrode was placed directly on the slice
approximately 100 - 200 µm away from the carbon fiber microelectrode. The parameters
for detecting DA at the electrode surface were completed using a triangle waveform
where the electrode potential was initially held at –0.4 V versus an Ag/AgCl reference
electrode, ramped up to +1.2 V, and then returned to –0.4 V at 400 V/s at a frequency of
10 Hz (7, 44, 53). DA release was evoked every 5 min by a one pulse monophasic
stimulation (350 µA, 60 Hz with 4 ms pulse width) from the stimulating electrode. All
electrode and stimulation parameters were controlled by TH software. Stable baseline
DA dynamics (release and re-uptake) were measured for at least 30 min.
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After stable DA release was recorded, superfusion of METH began with
increasing concentrations (0.01–10 µM) delivered to the slice every 30 min. To evaluate
DA’s affinity for DAT, slice FSCV was used with METH. METH, a competitive inhibitor
for the DAT, decreases the amount of DA taken back up into the neuron. The
competitive inhibition of DA reuptake is reflected as an increase in the apparent Km
(DA’s affinity for the DAT) (53). Equation 4.1 below shows how apparent Km is
calculated, where Km is the Michaelis-Menton constant and Ki is the inhibition constant.
The Ki values are calculated from the slope of the linear regression of METH
concentration versus apparent Km values (shown in equation 4.2). The value of Km
chosen was 0.16 µM, as previously reported in literature (53, 78-80).
Apparent Km = Km x (1 + [i]/Ki)

(4.1)

Slope = ∆y/∆x = Km/Ki

(4.2)

Increasing concentrations of METH were applied to the brain slice since it was
previously shown that cumulative concentrations of perfused drugs over a slice do not
affect DA release and uptake parameters (53).
Electrodes were post-calibrated with 3 µM DA and the peak oxidation current
was converted to concentration. The current versus time plots were fit by non-linear
regression using LabVIEW National Instrument software as described by John and
Jones (53). Using a Michaelis-Menton base kinetic model (7) peak amplitude of release
([DA]p), DA uptake kinetics (maximum velocity, Vmax), and DA’s ‘apparent’ affinity for the
transporter (Km) were determined by fitting DA concentration versus FSCV time traces.
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4.2.4 Locomotor activity
Mice were separated into singly housed cages 24 h prior to locomotor analysis.
On the day of analysis, mice were transported from the animal facility to the testing
facility, their food and water removed, and their home cage was placed into the
locomotor activity static chamber. Mice were allowed to habituate for 1 h to minimize the
stress of transportation and the novel environment. Spontaneous locomotor activity was
recorded using 3 sets of 16-beam infrared (IR) emitter-detector arrays (Med Associates,
St. Albans, VT) (81). Interruptions of IR beams resulted in an analog signal being
recorded by automated activity software (Open Field Activity Software [SOF-811], Med
Associates, St. Albans, VT). This system quantified total beam breaks in both the
vertical and horizontal planes, specifically encoding measures of distance traveled (cm;
calculated from number of breaks of adjacent beams), ambulatory time (s), and number
of rears. Baseline ambulatory distance was measured for a total of 2 h and binned into
10 min periods. To determine locomotor stimulation following METH administration,
baseline activity was determined for the first hour then mice were then injected with
saline (1.0 mL) i.p. and locomotor activity was collected for a second hour. Mice were
then injected with METH (1.0 mg/kg) and locomotor activity was collected for an
additional 2 h.
4.2.5 Statistical analysis
Neurochemical data analysis was performed using GraphPad Prism® software.
Values were reported as mean ± standard error of mean (SEM) with the criterion for
statistical significance set to P < 0.05.
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For zero-net flux analysis linear regression analysis, the x-axis represents the
concentration of DA being perfused into the probe determined by in vitro analysis (DAin),
and the y-axis represents the difference of DAout, which is defined as the concentration
of DA in the dialysate sample from DAin (75). The point at which the regression line
crosses the x-axis is known as DAext and indicates the basal extracellular concentration
of DA. The slope of the regression line was used to determine the in vivo recovery of
DA (Ed, dialysate extraction fraction) (82). Student’s t-tests were used to determine if a
significant difference existed between the genotypes with respect to DAext, extracellular
metabolite concentrations, and metabolite/DA ratio.
Release and uptake, as determined by FSCV, were analyzed using the
Michaelis-Menten kinetic based model which determines changes in [DA]p, Vmax, and
apparent Km (53, 79, 83). To determine differences in electrically stimulated DA uptake
and release between genotypes, two-tailed Student t-tests were used.
Locomotor activity, baseline and METH-induced, were analyzed (IBM SPSS®
Statistics for Windows) using a 2 x 3 x 12 three-way, repeated measures analysis of
variance (ANOVA) with Genotype (WT or BDNF+/-) as the between-subjects factors, and
month (12, 15, or 18) and the 12 time blocks as nested within-subjects factors.
4.3 Results
Slice voltammetry experiments and analysis was conducted by Francis K. Maina, Ph.D.
One of the main phenotypic differences reported between wildtype and BDNF+/mice is that BDNF+/- mice are often heavier than their wildtype counterparts, though the
point at which the divergence in weight starts is controversial (64, 65, 123). In the
present study, mice were weighed monthly starting at 3 months of age through 18
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months to determine when the BDNF+/- mice showed the typical weight gain compared
to the age matched wildtype mice. BDNF+/- mice were significantly heavier than their
wildtype counterparts as demonstrated by the main effect of genotype (Figure 4.1, F1, 277
= 87.78, P < 0.001). As shown in Figure 4.1, a two-way ANOVA indicates no difference
with respect to the main effect of time (P = 0.19) or an interaction (P = 0.95). To
determine if weight was a factor in total locomotor activity, wildtype and BDNF+/- mice
weights were analyzed and compared to distance traveled. No difference was observed
between heavier mice (40–50 g) and the lean mice (22–30 g) in the amount of distance
traveled in cm during a 2 h period, regardless of the genotype (data not shown).

Figure 4.1 Monthly weight in grams of wildtype (WT) and BDNF+/- mice from 3 to 18
months of age. BDNF+/- mice were significantly heavier compared to their wildtype
littermates. Inset shows monthly weights from 12–18 months of age. Each point
represents the mean ± SEM for each genotype (n = 21–24/genotype). Two-way ANOVA
showed main effect of genotype (***P < 0.001).
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Locomotor activity can be an indirect way to measure increases in extracellular
DA levels. Locomotor activity testing was conducted at 12, 15, and 18 months of age for
both wildtype and BDNF+/- mice to determine if basal activity was different. If differences
in locomotor activity were observed it could possibly be indicative of dopaminergic
alterations. Using a three-way repeated measures ANOVA analysis, no significance was
observed for genotype (P = 0.96) or interaction (Figure 4.2; P = 0.37), though a
significant main effect of time was observed (F11, 374 = 3.81, P < 0.001), and shown in
Figure 4.2A–C. Total ambulatory distance for each genotype at 12, 15, and 18 months
decreased as the session progressed. No other significant interactions were observed.

Figure 4.2 Homecage locomotor activity for wildtype (WT) and BDNF+/- mice as they
age from 12 to 18 months. A) Ambulatory distance (in cm) for 12 month old mice. B)
Ambulatory distance (in cm) for 15 month old mice. C) Ambulatory distance (in cm) for
18 month old mice. D) Cumulative distance traveled during the 2 h at 12, 15, and 18
months of age.
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Figure 4.3 DA zero-net flux in the CPu of wildtype and BDNF+/- mice. Linear regression
analysis of DA levels from wildtype (WT) and BDNF+/- mice. Apparent extracellular DA
levels (DAext) are represented by the x-intercept. Inset shows mean ± SEM of the
uncorrected DA concentration (extraction fraction; Ed), apparent [DAext], and slope for
both WT and BDNF+/- mice (n = 11–12/group).
Microdialysis experiments were used to determine the influence of a lifelong
reduction of BDNF has on the DA system. The uncorrected extracellular DA levels were
averaged from three to four baseline fractions, and no difference was observed between
the wildtype (2.2 ± 0.3 nM) and BDNF+/- (2.5 ± 0.5 nM) mice (Figure 4.3 inset; P = 0.86).
Using the in vivo microdialysis method of zero-net flux (75), corrected extracellular DA
levels (DAext), and the slope of the regression line (extraction fraction, Ed) for both
wildtype and BDNF+/- mice were evaluated in the CPu. DAext determined from the linear
regression line of the zero-net flux experiment (Figure 4.3, x-intercept), for both wildtype
and BDNF+/- mice, showed extracellular DA levels at 5.5 ± 0.8 nM and 7.6 ± 1.5 nM,
respectively (Figure 4.3 inset; P = 0.21). At 18 months of age, both genotypes had
corrected extracellular DA (DAext) concentrations in the CPu consistent with literature
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(44, 133, 134). The Ed did not differ between the wildtype (0.47 ± 0.65) and BDNF+/(0.33 ± 0.58) mice (Figure 4.3 inset; P = 0.15).
DA’s metabolites, DOPAC and HVA, were also evaluated using in vivo
microdialysis in both genotypes (Figure 4.4A). Aged BDNF+/- mice had significantly
higher DOPAC (710 ± 140 nM, n = 10) and HVA levels (710 ± 110 nM, n = 9) compared
to their aged wildtype littermates (DOPAC 400 ± 145 nM, n = 14, and HVA 470 ± 53 nM,
n = 15; P < 0.05). Extracellular DA turnover ratios were determined by dividing the
extracellular

metabolite

concentration

by

the

corresponding

uncorrected

DA

concentrations (Figure 4.4B). Aged BDNF+/- mice had 3-fold increase in their
[metabolite]/[DA] ratio for both the [DOPAC]/[DA] and [HVA]/[DA] (600 ± 160, n = 10;
and 630 ± 150, n = 10, respectively) compared to their aged wildtype counterparts
([DOPAC]/[DA] 190 ± 33, n = 14; and [HVA]/[DA] 230 ± 34, n = 14; P < 0.01).

Figure 4.4 Extracellular levels of the DA metabolites DOPAC and HVA and their
turnover ratios. A) Extracellular concentration of DOPAC and HVA levels measured by
microdialysis from the CPu. B) Extracellular [DOPAC]/[DA] and [HVA]/[DA] ratios. Data
are mean ± SEM (n = 10–14). *P < 0.05 as compared to wildtype (WT) mice (Student’s
t-test). B) **P < 0.01 as compared to WT mice (Student’s t-test).
Slice FSCV examined electrically evoked DA release and DA uptake by a single
pulse in the CPu of both aged wildtype and BDNF+/- mice. Figure 4.5A shows
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representative concentration versus time plot for both genotypes with their
corresponding cyclic voltammogram (Figure 4.5A inset). Electrically-evoked DA release
([DA]p) did not differ between genotypes at 18 months of age (wildtype mice: [DA]p = 1.8
± 0.1 µM, n = 19; BDNF+/- mice: [DA]p = 2.1 ± 0.2 µM, n = 11; Figure 4.5B). Similarly
DA uptake, Vmax, was not different between genotypes at this age (Figure 4.5C, wildtype
mice: Vmax = 4.1 ± 0.3 µM/s, n = 18; BDNF+/- mice: Vmax = 4.0 ± 0.2 µM/s, n = 12).

Figure 4.5 Slice FSCV of presynaptic striatal DA dynamics. A) Representative current
versus time electrically-evoked DA release and uptake in the CPu from wildtype (WT)
and BDNF+/- mice with corresponding cyclic voltammogram indicating DA detection. B)
Average electrically evoked DA release ([DA]p) from the CPu of aged mice. C) Average
striatal DA uptake rates (Vmax). D) The average ratio of phasic-to-tonic for young adult
(3-5 months) and aged (18 month) mice in the CPu. Data is represented as mean ±
SEM (n = 11–17, **P < 0.01).
As the adult BDNF+/- mice age, electrically evoked striatal DA release changes
with respect to time. Where young BDNF+/- mice had decreased electrically evoked
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striatal DA release, the aged BDNF+/- mice electrically evoked DA release did not
change with respect to their wildtype littermates (44). As a result of this difference in
evoked DA release in the BDNF+/- mice as they age, tonic and phasic DA transmission
in both young adult (4 months) and aged (18 months) wildtype and BDNF+/- mice were
observed by varying the stimulation pulses (p) from 1p (tonic) to a 5p (phasic) train.
Two-way ANOVA revealed a main effect of age in BDNF+/- mice with respect to phasicto-tonic (5p/1p) DA signaling (Figure 4.5D, F1, 49 = 10.23, P < 0.01). There was no main
effect of genotype or genotype X age interaction (F1, 49 = 0.22, P = 0.64 and F1, 49 = 2.36,
P = 0.13, respectively).
Similar to evoked DA release, DAT functionality increases in the aged BDNF+/mice to the DAT uptake rates observed in the aged wildtype mice. Therefore, another
experiment using microdialysis was done to better understand DAT dynamics in aged
mice using METH. METH was used to probe the transporter functionality with
microdialysis, FSCV, and locomotor activity. METH is known to disrupt the vesicular
monoamine transporters ability to sequester DA in vesicles resulting in a greater efflux
of DA into the extracellular space (135). In our microdialysis experiment, 60 min of
baseline samples were collected, at which time the mouse was administered 1.0 mg/kg,
i.p. injection of METH (Figure 4.6A), and samples were collected for an additional 120
min. Extracellular DA levels are reported as a percent of DA baseline. METH induced a
maximal response 40 min after an injection in both genotypes (wildtype: 561% and
BDNF+/-: 724%). Using a two-way repeated measure ANOVA main effect time (F8, 208 =
30.47, P < 0.001) was observed but not genotype (F1, 208 = 1.52, P = 0.23).
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Locomotor activity was assessed in the aged mice after an acute injection of
METH (Figure 4.6B). Using two-way ANOVA, there was a significant main effect of time
(F29,

1106

= 2.0, P < 0.01), but no difference was observed between genotypes or an

interaction (F1, 1106 = 0.35, P = 0.55, and F29, 1106 = 0.51, P = 0.99, respectively). At the
190 min time point, a sharp increase in locomotor activity is seen for both genotypes
which continued for 30 min before descending back towards baseline locomotor activity
levels. The effect of a single METH concentration was measured for 30 min. Figure
4.6C shows non-linear fitting (Figure 4.6D is the linear portion of 4.6C) of a dosedependent increase in apparent Km with increasing METH concentrations. This increase
in apparent Km represents a decrease in affinity of DA for its transporter. Both aged
genotypes had a dose dependent increase in the apparent Km values. Two-way ANOVA
for the analysis of non-linear fitting showed a significant main effect of METH treatment
(F6, 316 = 96.50, P < 0.001), but no significant difference in apparent Km was observed
between the aged mice at either genotype (P = 0.89). There was no interaction between
genotype X treatment (P = 0.99), thus, the potency of METH is the same across the
aged genotypes. To quantify Ki, DA uptake inhibition, values for METH, the slopes of
the lines from Figure 4.6D were calculated, and slopes are similar for both genotypes
(wildtype mice: 0.026 ± 0.002, n = 14, and BDNF+/- mice: 0.021 ± 0.002, n = 12).
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Figure 4.6 Influence of methamphetamine (METH) on striatal DA dynamics and
locomotor behavior. A) Microdialysis measurement of METH induced dopamine release,
reported as percent baseline. B) Ambulatory distance traveled of wildtype (WT) and
BDNF+/- mice. Baseline was collected for the first 2 h then saline was injected (arrow)
and the ambulatory distance was measured. At the 180 min mark, an i.p. injection of
METH (1 mg/kg) was administered and ambulatory distance was measured. (n = 17–
25/per group). C) Non-linear fitting of dose-dependent increase in apparent Km values
with increasing METH concentrations using FSCV. D) Linear regression plots of the
apparent Km values using FSCV with increasing concentrations of METH.
4.4 Discussion
A lifelong reduction in BDNF results in a striatal dopaminergic system which
changes with respect to age. Instead of the aged BDNF+/- mice having a
hyperdopaminergic striatal system as seen in the young BDNF+/- mice, the aged
BDNF+/- mice dopaminergic system appears to ‘normalizes’ to a level comparable to the
young adult and aged wildtype mice with respect to extracellular DA levels, DA release,
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and DAT uptake rates. Extracellular DA levels in the aged BDNF+/- mice are attenuated
from 12.0 nM in young, to 7.6 nM in aged BDNF+/- mice (see Table 4.1) (44).
Interestingly, extracellular DA levels in aged BDNF+/- mice decrease to levels similar to
the aged wildtype mice. Our steady state striatal DA concentrations are in agreement
with our basal uncorrected DA levels (see Figure 4.3 inset) where no differences
between the genotypes were observed. However, a previous microdialysis study in
aged BDNF+/- mice reported a decrease in uncorrected extracellular DA levels
compared to their wildtype counterparts in both young adult (3 months) and middle aged
mice (12 months) (64). Strain and age differences, as well as method parameters like
microdialysis probe size (1 vs. 2 mm probe) and slight medial-lateral variation in probe
placement in the CPu may account for these divergences in extracellular DA levels
between our aged results and those reported by Boger (64). No changes in extracellular
DA levels further suggest that there is no significant degeneration of striatal DA neurons
in these aged animals (136, 137). Supporting the hypothesis of the absence of neuronal
degeneration, is cell morphology of nigral-striatal DA neurons and MSNs in the dorsal
striatum were no different in aged BDNF+/- mice (18 to 24 months old) (23, 123, 138).
#

.

Young WT

Young BDNF

DAext (nM)

5.0 + 0.2

12.0 + 0.4

DOPAC (nM)

410 + 70

HVA (nM)

+/- #

Aged WT

Aged BDNF

5.5 + 0.8

7.6 + 1.5*

330 + 90

400 + 145

710 + 140*

465 + 65

560 + 120

467 + 53

710 + 110

Release ([DA]p) (µM)

1.8 + 0.1

1.2 + 0.1

ƗƗƗ

1.8 + 0.1

2.1 + 0.2***

Uptake (Vmax) (µM/s)

4.1 + 0.1

2.7 + 0.1

ƗƗƗ

4.1 + 0.3

4.0 + 0.2***

ƗƗƗ

+/-

Table 4.1 Young mice (3–5 months) verses aged mice (18 months). Student-t test
showed significance between young wildtype (WT) and BDNF+/- (ƗƗƗP < 0.001), and
between young BDNF+/- and aged BDNF+/- (*P < 0.05, ***P< 0.0001). #Data from (44).
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Although no alterations were observed in extracellular DA levels between aged
wildtype and BDNF+/- mice, there was an increase in DA metabolism as measured by
microdialysis. An increase in both extracellular DOPAC and HVA levels in the aged
BDNF+/- mice could contribute to the reduced extracellular DA levels in the aged
BDNF+/- mice to that of the aged wildtype mice. Monoamine metabolic abnormalities
have been observed in BDNF-deficient mice with respect to the serotonin system (65).
Similarly, young (Table 4.1, (44)) and aged neurochemical measurements parallel the
dysregulation of serotonin in aged BDNF+/- mice by Lyons (65). Together, the
dysregulation of the aging DA and serotonin systems in BDNF+/- mice strongly supports
the hypothesis that normal BDNF levels are required for proper monoamine functioning.
Young adult BDNF+/- mice showed no metabolism or synthesis differences (44). Thus, it
appears as the BDNF+/- mice age, activity or function of metabolic enzymes such as
MAO is enhanced, and age-related changes in MAO isoforms are not uncommon. For
example, levels of the MAO isoforms diverge as C57BL/6J mice age, where MAO-A
levels were steady as the animals aged to 25 months, while MAO-B levels gradually
increased (129). Furthermore, a MAO-B transgenic mouse with 2.5 times the
expression of MAO-B shows a 60% reduction in striatal DA levels measured by tissue
content at 2–6 months of age, with a concomitant 50% reduction in dopaminergic
substantia nigra (SN) neurons by 14 months of age (67) suggesting a pivotal role for
MAO in regulating the DA system during the aging process. Elevated MAO-B levels
could be detrimental to the surrounding systems because increased DA metabolism
could lead to an elevated production of ROS. In the aged BDNF+/- and wildtype mice,
there are no differences in striatal DA levels are observed, which contradicts previous

77
literature findings with respect to elevated MAO-B expression (67, 129). To further
support the hypothesis that MAO is upregulated or has increased functionality in aged
BDNF+/- mice, the extracellular turnover ratio between [DOPAC]/[DA] and [HVA]/[DA]
are significantly elevated in BDNF+/- mice compared to their age matched wildtype mice.
The increase in the [DOPAC]/[DA] ratio in aged BDNF+/- mice suggests an elevation in
MAO activity or function throughout the lifespan of the BDNF+/- mice. To better
understand these monoaminergic changes in aging mice, future studies should focus on
the expression and activity of the MAO isoforms in the striatum of aged BDNF+/- mice to
fully assess these alterations in metabolism. Increases in MAO activity may provide
crucial evidence affirming the metabolic alterations observed in the aged BDNF+/- mice.
Extracellular DA levels are not strictly regulated by metabolism. The dominant
mechanism for regulating extracellular DA is uptake via the DAT. As the BDNF+/- mice
aged from 3 to 18 months, DA uptake rates increased in the aged BDNF+/- mice to rates
similar to their aged matched wildtype mice. Thus, young adult BDNF+/- mice have a
slower DAT function that is likely to cause their elevated striatal extracellular DA levels
(44). As the BDNF+/- mice age, DAT function appears to increase approximately to the
uptake rate of the aged wildtype mice. Presumably, this faster rate of DA clearance
leads to decreasing extracellular DA levels in aged BDNF+/- mice. Autoradiography
studies support this hypothesis since DAT expression is not different between the
genotypes (64). Together, these findings support the proposition that DAT function
increases with age in the BDNF+/- mice.
When a 100 ng/mL infusion of BDNF was applied to young adult BDNF+/- mouse
striatal slices, it increased stimulated DA release by 20%, while BDNF infusion resulted
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in no difference in stimulated DA levels in the wildtype mice (44). Taken together, these
results from the young mice suggest that BDNF’s primary role is to regulate DA release.
Based upon the findings by Bosse et al., and our current findings that suggest DA
dynamics in BDNF+/- mice normalize with age, the next step was to evaluate the role of
endogenous BDNF on tonic and phasic DA release between young and aged mice (44).
The frequency of DA release in the dorsal and ventral striatum can be regulated either
endogenously or exogenously by other factors (139). Young adult BDNF+/- mice showed
a 40% reduction in evoked DA release during a 1 pulse (1 p) stimulation in the CPu and
correlated with a stronger facilitation of DA release during a 5 p ‘phasic-like’ stimulation.
Furthermore, young and aged wildtype mice had a relatively greater evoked DA release
by a 1 p stimulation in the CPu when compared to the younger BDNF+/- mice, and upon
a phasic-like stimulation the relative DA response was similar between young and aged
wildtype mice. Interestingly, the aged BDNF+/- mice parallel their wildtype counterparts
with restored 1 p release in which no difference was observed in the aged BDNF+/- mice
phasic-like release. The tonic and phasic results in the CPu of young wildtype and
BDNF+/- mice parallels the tonic versus phasic results between the dorsal and ventral
striatum (139) further suggesting that endogenous BDNF levels are a strong contributor
to the regulation of DA release in the CPu, particularly in young animals. Measurements
of BDNF protein levels in BDNF+/- mice by others show significantly lower levels at three
distinct time points versus their wildtype littermates (64). Although Boger et al. reported
no difference on striatal BDNF levels due to age, there appears to be a trend toward
decreased BDNF levels with age across the two genotypes (64). In both genotypes, the
difference in BDNF levels in 21 month old mice are less than at 3 months of age, further
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suggesting that BDNF dynamics are more similar between the two genotypes at
advanced ages versus a younger age (64). Our striatal DA results are in agreement with
the notion that there is a greater difference in striatal BDNF levels when mice are
young. As the mice age, the difference in BDNF levels is minimized resulting in the two
aged genotypes appearing more similar with respect to their DA dynamics.
With these significant alterations in the aging striatal DA system of BDNF+/- mice,
we further evaluated the effect of an acute dose of METH. Numerous studies have
examined the effect of psychostimulants, specifically amphetamine related compounds
in BDNF+/- mice. Administration of psychostimulants to BDNF+/- mice blunts their
monoamine response compared to their wildtype littermates (30, 65, 140). For instance,
Saylor and McGinty observed no difference in the TH synthesis after an acute injection
of amphetamine in 3 month old BDNF+/- mice, suggesting an abnormality in DA release
and not DA synthesis (140). An acute injection of amphetamine elevated mRNA
expression of TrkB, BDNF, and TH in the CPu of wildtype mice, but no differences in
these expression levels were observed in the BDNF+/- mice, suggesting that
amphetamine is responsible for changes in gene expression of not only TH, but also
BDNF and its receptor TrkB (140). Furthermore, Dluzen and colleagues proposed that
young BDNF+/- mice are protected from the neurotoxic effects of amphetamines due to
this reduced DA uptake and release (96). Many of these amphetamine studies have
been done in younger mice, and to better understand psychostimulant effects on a DA
system with a lifelong reduction of BDNF, an acute injection of METH was administered
to the aged BDNF+/- mice. Similar to the results throughout this paper, METH-induced
DA release via in vivo microdialysis and locomotor activity was not different between the
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two genotypes. No alterations in DA dynamics of aged BDNF+/- mice may be a result of
the DAT having an increase in functionality in comparison to the young BDNF+/- mice.
When probing the functionality of the DAT with METH, the Km values were not
significantly different between the aged genotypes, suggesting the potency of METH’s
effects on DAT is similar across genotypes. These results contradict our predicted
hypothesis, that METH-induced stimulation would potentiate the release of extracellular
DA in aged BDNF+/- mice, which was based on the initial belief that BDNF+/- mice have a
slower rate of DAT uptake or decrease in function versus aged wildtype mice. The
alterations that were observed in DAT function suggests that the BDNF+/- mice are not
protected from METH’s effects as proposed by Dluzen (93). Our results would suggest
that the aged BDNF+/- mice are equally susceptible to METH-induced DA release, via
the reversal of DAT, to being no longer different from their aged wildtype mice (93).
One caveat in using knockout animals, even animals with only a 50% reduction
of BDNF, is that the gene mutation has been present since conception and numerous
neuroadaptations are possible. Thus, it is possible that other neurotrophic systems have
taken on a more prominent role, leading to these age-dependent DA alterations
occurring in the BDNF+/- mice. One possible candidate is neurotrophin 4 (NT-4), which
also binds and acts on the TrkB receptor. For example, Hill et al., demonstrated that
striatal TrkB levels in 3 month old BDNF+/- mice are not different from wildtype mice,
while striatal NT-4 levels are increased in BDNF+/- mice compared to their wildtype
littermates (61). These results suggest that the NT-4 system may be upregulated and
compensating for the decrease in BDNF levels. To further validate this hypothesis,
experiments using double knockout mice lacking both BDNF and NT-4 showed that
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these mice had a 25% decrease in TH cells in a visceral sensory population of the
nodose–petrosal ganglion complex compared to only BDNF+/- mice (141). If NT-4
increases with respect to age, then future experiments need to evaluate at what age
NT-4 begins to take on a more compensatory role in the striatum of BDNF+/- mice.
Overall, our results on the striatal dopaminergic system in the aged BDNF+/- mice
demonstrate that this system dynamically adjusts to lifelong reductions in BDNF. In
particular, aged BDNF+/- mice are not more susceptible to the aging process and the
detrimental effects associated with aging. Instead, it appears that the DA system adjusts
accordingly as these mice age. Aged BDNF+/- mice show a decrease in extracellular DA
levels, and potentiated DA release, and uptake compared to their younger counterparts
(44). This normalization of the dopaminergic system in BDNF+/- mice appears to be
persistent as the mice age, and is also apparent with respect to locomotor activity, in
which no difference is observed between the BDNF+/- mice and their wildtype
counterparts between 12 to 18 months of age. The results from the aged BDNF+/- mice
highlight the dynamic role that BDNF plays throughout the life of an organism;
specifically, with respect to the striatal DA system. However, the ability of the DA
system to normalize with respect to age begs for a deeper understanding of the
mechanism that causes these changes in BDNF+/- mice. Ultimately, these results will
assist our understanding on how life-long reductions of BDNF influence striatal DA
dynamics and may provide further insight on how lower BDNF levels increases ones
susceptibility to the detrimental diseases of the brain that can occur during aging
process.
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CHAPTER 5
Simultaneous Detection of Monoamine and Purine Molecules using
High-Performance Liquid Chromatography with a Boron-Doped
Diamond Electrode
(Portions from the text in this chapter were reprinted or adapted with permission
from Birbeck, J. A., and Mathews, T. A. (2013) Simultaneous Detection of Monoamine
and Purine Molecules Using High-Performance Liquid Chromatography with a BoronDoped Diamond Electrode, Anal Chem. Copyright (2013) American Chemical Society.)
5.1 Introduction
The detection of neurotransmitters in an in vivo or in vitro environment typically
employs a separation operation such as high performance liquid chromatography
(HPLC) or capillary electrophoresis with corresponding detection methods such as
electrochemical (monoamines), UV absorbance (amino acids), fluorescence (amino
acids), or mass spectrometry (peptides) (44-47). A notable bioanalytical challenge is the
simultaneous detection of multiple neurotransmitter families together using a single
analytical tool. Mass spectrometry has successfully been used to simultaneously detect
monoamines, purines, and amino acids through a derivatization step with benzyl
chloride (142). Although mass spectrometry is frequently the method of choice for
detecting multiple analytes across various families, limitations of using this technique in
neurochemistry include the cost and expertise needed to analyze the samples. Instead,
most neuroscientists use HPLC with electrochemical, UV, and fluorescence detection,
to separate, detect, and quantify neurotransmitters. Electrochemical detection has been
used to identify monoamines and amino acids, although typically not simultaneously
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(143, 144). Often, electrochemical detection, in conjunction with HPLC, utilizes a glassy
carbon amperometric cell or a porous carbon coulometric cell and is limited to the
detection of molecules which are electrochemically active, such as the monoamines
dopamine (DA), serotonin (5-HT), and their metabolites (44, 45, 76). Amino acids such
as glutamate, glutamine, and γ-aminobutyric acid (GABA) also are detected
electrochemically, but are derivatized, for example, using o-phthalaldehyde (OPA) or
naphthalene-2,3-dicarboxaldehyde (NDA) (143, 145-147). However, derivatization using
OPA has disadvantages such as instability, chromatographic contamination, and
incompatibility with biological matrixes such as dialysate and tissue content samples
(145, 148, 149).
Within the last few decades, alternative carbon-based electrode materials have
been discovered and developed, with one of particular interest being the boron-doped
diamond (BDD) electrode. BDD electrodes began as home-built microelectrodes (51,
56, 150). The original laboratories pioneered the development and biochemical
application of the BDD electrode in many areas throughout neuroscience and also in
gastrointestinal tract and cancerous tumor (59, 150-153). In comparison with the carbon
electrode, the BDD electrode has a higher potential working range, decreased
background noise, electrochemical stability due to diamond surface coordination,
insensitivity to dissolved oxygen, and less susceptibility to electrode fouling (51, 52).
These advantages, along with the advent of a new commercially available BDD disk
electrode for use with HPLC, make the BDD electrode an attractive detection method
for molecules with higher oxidation potentials and those that are easily oxidizable.
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The objective of this work was to develop a method based on the commercially
available BDD electrode for the simultaneous detection of adenosine (Ado) and DA.
Little is known about the in vivo function of Ado, but there is considerable data linking
DA and Ado through their respective receptors, the DA D2 receptors and the Ado A2A
receptors (2, 154, 155). Furthermore, DA and Ado were chosen because of their
intertwining relationship in the brain and in diseases and disorders like Parkinson’s
disease and schizophrenia (2, 11, 156, 157). Multiple detection methods are available
for the analyzing DA and Ado such as HPLC coupled with electrochemical and UV
detection, capillary LC with electrochemical detection, mass spectrometry, or fast scan
cyclic voltammetry (9, 45, 54, 55, 158). However, drawbacks of some of these methods
are long analysis time from a two-component system, poor detection limits, and the
ability to measure only one or two of the analytes at a time (45, 54). To date, the
detection of Ado using carbon-based electrode cells (glassy or porous) with HPLC has
not been achieved. This limitation relates to the fact that oxidation of Ado at a bulk
electrode is not feasible because of the high potential required to oxidize Ado
(approximately +1500 mV); potentials greater than +1000 mV cause surface oxidation,
instability, and high background noise with carbon-based electrodes (49). The
developed HPLC-BDD method described in this article shows the separation and
detection of nine molecules including DA and Ado and other members of the
monoamines and purine families in 28 min. The advent of developing a method that
determines multiple classes of neurotransmitters in a single run is valuable because
smaller sample size can be utilized, analysis costs will be lower, and fewer animals will
be sacrificed.
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5.2 Materials and Methods
5.2.1 Chemicals
Chemicals used for mobile phase, buffers, and standards were of HPLC grade or
higher purity and were purchased from Sigma-Aldrich (St. Louis, MO), Fisher Scientific
(Pittsburgh, PA), and EMD (Gibbstown, NJ). For DA, standards were made up in 1 mM
stock solutions by adding 0.1 M HClO4, 10% methanol, and 10 μg/mL ascorbic acid, and
stored at -80 °C until analysis. 3,4-Dihydroxyphenylacetic acid (DOPAC), homovanillic
acid

(HVA),

3-methoxytyramine

(3-MT),

norepinephrine

(NE),

5-HT,

and

5-

hydroxyindoleacetic acid (5-HIAA) were made up in 0.1 M HClO4 and stored in at -4 °C
until analysis. Ado and adenosine monophosphate (AMP) were made up in 0.1 M
HClO4 and at -80 °C stored until further use.
5.2.2 Analytical parameters
Isocratic monoamine and purine separation were completed using a Shimadzu
LC-20A HPLC instrument coupled to a Thermo Scientific ESA Coulochem III detector.
The electrochemical cell used for detection was a Thermo Scientific ESA model 5041
analytical cell with a BDD disk electrode (Figure 5.1A). The column used was a Thermo
Scientific Acclaim Trinity P1 column (100 x 3 mm, 3 μm particle size). Mobile phase was
composed of 45 mM (NH4)3PO4, 1.1 mM Na4P2O7, 4% acetonitrile, and was adjusted to
pH 3.00 using phosphoric acid (85 wt %). The mobile phase was subsequently purged
with argon and then sonicated. The flow rate was set at 0.65 mL/min. The potential for
simultaneous detection of DA and Ado was determined by a hydrodynamic
voltammogram, and the optimal potential to detect both analytes was +840 mV versus a
palladium reference electrode. The approximate analysis time for both DA and Ado was
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less than 10 min. For a more comprehensive analysis of monoamines such as DOPAC,
HVA, 3-MT, NE, 5-HT, and 5-HIAA, and the purine AMP, the total analysis time was 28
min. Analyte peak areas for monoamine and purine molecules were determined against
known standards and integrated using LC Solutions Shimadzu Software.
For isocratic carbon-based electrochemical cell analysis, a Thermo Scientific
ESA coulometric cell model 5014B microdialysis cell with potentials for the working
electrodes 1 and 2 (E1 and E2) set at -150 and +220 mV, respectively, versus a
palladium reference electrode. The mobile phase used for separation of monoamines at
the carbon electrode consisted of (in mM concentrations) 75 NaH2PO4 monohydrate,
1.4–1.8 1-octanesulfonic acid, 0.125 ethylenediaminetetraacetic acid (EDTA), 10%
acetonitrile, 0.002% triethylamine; adjusted to pH 3.00 with phosphoric acid (85 wt %).
The mobile phase was then purged with argon before being placed onto the system,
and the flow rate was set to 0.35 mL/min. The column used for analysis was a
Phenominex Luna 2.5 μm C18 (2)-HST (100 x 3 mm, 2.5 μm particle size). The analyte
peak areas for monoamines were analyzed against known standards and integrated
using LC Solution Shimadzu Software.
5.2.3 Tissue content
The animals used in the tissue-content experiments were female C57BL6/J mice
that were bred in-house. Breeder mice were obtained from Jackson Laboratories (Bar
Harbor, ME). Mice were sacrificed by cervical dislocation, and their brains were rapidly
removed. The brain regions of the frontal cortex and striatum were dissected out, rapidly
frozen in liquid nitrogen, and stored at -80 °C until analysis. On the day of analysis,
tissue was removed from the freezer and allowed to thaw on ice for approximately 30
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min. A volume of 250 µL of 0.1 M HClO4 was added to each vial of tissue and the tissue
was homogenized. Vials were centrifuged for 10 min at a rate of 12000 rpm at 4 °C. A
20 µL volume of supernatant was injected onto the HPLC instrument. Tissue
concentrations of monoamines and purines were determined using a linear regression
analysis from peak areas that were integrated and quantified against a set of standards
using LC Solutions Shimadzu Software. Monoamine and purine tissue levels are
represented as nanograms monoamine or purine per milligram of protein. Protein
values were measured using Pierce bicinchoninic acid (BCA) protein assay kit. All
experiments and procedures were in accordance with the National Institute of Health
Animal guidelines, were approved by Wayne State University Institutional Animal Care
and Use Committee, and were designed to minimize discomfort in the animals.
5.3 Results and Discussion
5.3.1 Electrode Characterization
Figure 5.1B shows a scanning electron microscopy (SEM) image of the relatively
uniform surface of a BDD disk electrode (length along the straight edge: 1.20 cm, radius
of arch = 1.50 cm) used for experimentation herein, which was manufactured and is
disturbed by Thermo Scientific ESA (50). The design of the Thermo Scientific ESA 5041
analytical cell is versatile in that it accommodates the BDD electrode as well as other
various electrode materials such as glassy carbon, platinum, silver, and gold.
Furthermore, no pretreatment of the BDD electrode is required after it has been placed
into the 5041 Analytical Cell.
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Figure 5.1 A) Schematic amperometric cell design for the commercially available borondoped diamond electrode manufactured by Thermo Scientific ESA Inc.™ B) SEM image
of the bare electrode surface taken at 15,000 x 2.0 V.
5.3.2 Mobile Phase Parameters
Initial experiments focused on determining the proper mobile-phase configuration
for the simultaneous detection of DA and Ado using the BDD electrode. Numerous
mobile phases were examined with the BDD electrode, including the sodium phosphate
mobile phase that is described for use with the porous carbon electrode in Materials and
Methods and a sodium acetate mobile phase. However, there were limitations with
these mobile phases, including that the sodium phosphate mobile phase was able to
detect only DA and not Ado and generated too many unknown peaks and the presence
of EDTA in the mobile phase at potentials greater than +500 mV lead to an increase in
the background noise. Even though the sodium acetate mobile phase was able to
detect both DA and Ado, after three days of analysis, the mobile phase was completely
unusable because of increasing background noise due to the oxidation of the acetate.
Methanol was also evaluated in place of acetonitrile, but it also increased the
background noise in a manner similar to that of EDTA with the BDD electrode.
Therefore, acetonitrile was used. The final mobile phase that was developed consisted
of ammonium phosphate, sodium pyrophosphate, and acetonitrile, and lead to reliable
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separation and detection of DA and Ado. After further refinement of the current mobile
phase, NE, DOPAC, HVA, 3-MT, 5-HT, 5-HIAA, and AMP were clearly separated.
5.3.3 Hydrodynamic Voltammogram
A hydrodynamic voltammogram was constructed for DA and Ado to determine
the optimal working potential sufficient for the simultaneous detection of both of these
molecules using the BDD electrode. The initial potential for the hydrodynamic
voltammogram was set to 0 mV, and the potential was subsequently increased by +20
and +100 mV until a final potential of +1200 mV was obtained. The responses of DA
and Ado were measured in triplicates using a 300 nM standard, and the averages are
plotted as the percentages of the normalized response in Figure 5.2. The optimum
oxidation potential for detecting DA and Ado at the BDD electrode were found to be
+740 mV and +1200 mV, respectively. The DA oxidation potential reported here is
slightly negative compared to previous reports using BDD electrode (150, 159). This
shift in DA oxidation is due to the fact that the reference electrode is palladium and not
the standard Ag/AgCl reference electrode, where the palladium electrode detection is
~300 mV lower than the Ag/AgCl reference electrode. When this potential difference is
taken into account, the equivalent applied potential at a BDD electrode using a Ag/AgCl
reference electrode would be approximately +1040 mV, which is in agreement with
literature for DA detection (150, 159). The large oxidation potential difference observed
between DA and Ado at the BDD electrode is similar to results obtained using a carbonfiber microelectrode with a Ag/AgCl reference, where the peak oxidation separation was
~900 mV (55). For the BDD electrode method, a working potential of +840 mV was
chosen because it provided optimal detection for both DA and Ado (Figure 5.2, dashed
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line). Although +840 mV is not strictly the average of the two potentials, this oxidation
potential was specifically chosen because it is more sensitive for DA than for Ado. This
criterion was set because extra- and intracellular DA levels in the brain are reported to
be between 6- and 100-fold lower in concentration compared to Ado (44, 142, 144, 160,
161). Therefore, it is imperative that the sensitivity for DA be greater than that for Ado.

Figure 5.2 Hydrodynamic voltammogram to determine the optimal potential for the
oxidation of adenosine (○) and dopamine (■). Dashed line from the x-axis represents
the optimal potential selected for measuring adenosine and dopamine.
5.3.4 Linearity
To determine whether these analytes respond in a concentration-dependent
manner, linear calibration curves were created for both DA and Ado at different gains.
DA and Ado stock standards were diluted in water, injected onto the HPLC instrument,
and plotted as the area under the curve versus concentration. After the plots had been
constructed, linear regression analysis was used to determine the slope of the line
(sensitivity: Table 5.1), y-axis intercept, and correlation values (R2) for each analyte. At
a potential of +840 mV and gain of 5 nA (representing the lowest detection window), the
linear concentration ranges for DA and Ado were 1–100 nM and 1–400 nM, respectively
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(Figure 5.3). Both analytes had linear correlation values of at least 0.998. The sensitivity
for DA was 8.4 x 104, which was approximately twice the sensitivity of Ado (2.9 x 104)
(Table 5.1). We hypothesize that the difference in sensitivity is a result of the oxidation
potential chosen of +840 mV for this method, for which the hydrodynamic
voltammogram (Figure 5.2) shows a 100% response of DA oxidation, whereas only
~20% of Ado is oxidized at this potential. Again, the method was intentionally biased to
favor DA oxidation, because extracellular striatal DA levels (extracellular: 5–10 nM) are
significantly lower compared to Ado levels (extracellular: 40–210 nM) (14, 133, 134).
The total linear range detected for DA and Ado were 0.001–5 μM and 0.001–200 μM,
respectively (data not shown). The lowest detectable concentration observed for both
DA and Ado was at 1 nM, with a reporting limit of 0.5 nM. These lower limits are well
within the range of concentration monoamines and purines in biological systems.

Figure 5.3 Linear calibration curve for the oxidation of adenosine (○) and dopamine (■)
at a potential of +840 mV. Linear range for dopamine was 1–100 nM, and for
adenosine, 1–400 nM.
Comparisons between porous carbon and the BDD electrode can only be made
with respect to DA, as Ado is not detectable at the carbon surface. At a potential of
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+220 mV and gain of 2 nA, the linear concentration range for DA was from 0.5 to 15 nM.
DA calibration curves at the porous carbon routinely had linear correlation values of at
least 0.998. The average sensitivity for DA was 7.0 x 105, which was approximately 10
times higher than the sensitivity of DA at the BDD electrode. However, it must be noted
that our method for DA detection at the porous carbon electrode was optimized for
routine microdialysis measurements, which includes a 2.5-μm particle-size column
versus 3-μm particle-size column used with the BDD electrode. The lowest detectable
concentration for DA at the porous carbon electrode is 0.5 nM (data not shown). Thus,
the lowest detectable concentrations for DA were approximately the same for these two
electrode surfaces. Taken together, these results indicate that the BDD electrode can
compete very favorably to the porous carbon electrode with respect to DA, but the
advantage of the BDD electrode is its ability to detect purine molecules such as Ado.
We anticipate that, with future experimental refinements such as using a column with
smaller particles, the BDD electrode will be able to achieve the sensitivity and lowest
detectable concentration of DA that is seen with the porous carbon electrode as well as
improve upon these parameters with Ado.
5.3.5 Limit of Detection and Quantification
The limits of detection and quantification were determined using averages of 10
nM standards of DA and Ado fit to the calibration curve from Figure 5.3. Using
equations
Limit of Detection =

.

Limit of Quantification =

(5.1)
(5.2)
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where σ is the standard deviation and m is the mean (Table 5.1), the limit of detection
and quantification were determined for both DA and Ado. The limit of detection for DA
and Ado, calculated using eq 5.1, were determined to be 0.021 nM, and 1.2 nM,
respectively. The limits of quantification (eq 5.2) were determined to be 0.063 nM and
3.7 nM for DA and Ado, respectively.
5.3.6 Precision and Accuracy
To determine the accuracy and precision of the method, standard concentrations
of DA and Ado were assessed using the average relative percentage deviation (DEV,
%) and the relative standard deviation (RSD, %), which were calculated as
DEV (%) =

(5.3)

RSD (%) =

(5.4)

where m is the average calculated concentration and σ is the standard deviation.
The accuracy of the method was determined by measuring 10 nM standard of
DA and Ado in replicates and calculating their means and standard deviations. The
calculated accuracy of the method for DA and Ado (eq 3) demonstrated that the
standard values were within acceptable range for both analytes: 99% and 101%,
respectively. Furthermore, the precision of the method was quantitated (eq 4) with both
analytes being less than 10%, specifically, with DA at 7% and Ado at 3% (Table 5.1).
Table 5.1 Figures of merit for the simultaneous detection of dopamine and adenosine
using HPLC with BDD electrode.
Dopamine
Adenosine
Limit of Detection (nM)
0.021
1.2
Limit of Quantification (nM)
0.063
3.7
RSD (%)
7
3
DEV (%)
99
101
4
Sensitivity
8.4 x 10
2.9 x 104
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5.3.7 Analysis of monoamine and purine neurotransmitters
Once the electrochemical parameters for DA and Ado were validated, the
detection of other monoamines and purines was assessed. All monoamine and purine
standards were analyzed at +840 mV, gain of 20 nA, and standard concentrations of
300 nM were evaluated except for 5-HIAA, which was measured at 100 nM (Figure
5.4A). AMP cannot be observed in this representative chromatogram (Figure 5.4A)
because concentrations >300 nM are required for its detection at +840 mV. This HPLC
electrochemical method provides ample separation between analytes from both the
monoamine and purine families with an analysis run time of ~28 min (Figure 5.4A),
whereas a run time of less than 8.5 min was needed for DA and Ado. Taken together,
our results demonstrate the feasibility of using the BDD electrode not only to detect
easily oxidized species such as monoamines but also purine molecules, to provide a
more comprehensive analysis of neurotransmitters and even neurotransmission.
The validity of the method was determined using brain tissue samples from the
striatum and frontal cortex of female C57BL6/J mice, as both regions are known to
contain DA and Ado. Tissue-content analysis of monoamine and purine molecules was
performed using the same mobile phase as the standard chromatogram with the BDD
electrode. Eight molecules (six monoamines and two purines) were detected
simultaneously in approximately 28 min (Figure 5.4B). The DA metabolite HVA was
separated clearly in the standard chromatogram, but was not visibly defined in the
tissue-content sample chromatogram because of an overlap by an unknown peak.
Therefore, HVA levels could not be accurately determined (Figure 5.4B).
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Figure 5.4 A) Representative 300 nM standard chromatogram of adenosine (Ado), 3,4dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), dopamine (DA), 3methoxytyrosine (3-MT), serotonin (5-HT), and 100 nM 5-hydroxyindoleacetic acid (5HIAA) at an applied potential of +840 mV. B) Representative striatal tissue content
chromatogram with the appropriate neurotransmitters labeled.
To fully assess this method’s ability to accurately and quantitatively measure
monoamines and purines in biological samples, a side-by-side comparison was made
with the standard method used to detect monoamines using a porous carbon
electrochemical cell (model 5014B, Thermo Scientific ESA). Although the this cell is not
the same cross-flow cell design as used for the BDD electrode, comparison between
these two different cell types were made since the majority of tissue-content analysis in
the literature uses a porous carbon electrode (45, 162, 163). Tissue-content samples
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from the frontal cortex and striatum of mice were both run on two separate HPLC’s, one
with a porous carbon electrode and the other with the BDD electrode. The porous
carbon electrode detected all seven monoamine molecules, but was unable to detect
the purine molecules Ado and AMP, whereas the BDD electrode was able to detect all
six monoamines and two purines (Table 5.2). Furthermore, the BDD method accurately
detected six monoamines in the striatum and frontal cortex. Within the striatum, only 5HIAA levels were significantly different compared to those from the carbon electrode
(Student’s t-test, 5-HIAA detected at BDD at 35 ± 8 ng/mg protein and by carbon at 94 ±
20 ng/mg protein, P < 0.05). In the frontal cortex, 3-MT levels were significantly different
between the two electrode surfaces, where the BDD electrode measured a higher
concentration compared to the porous carbon electrode (Student’s t-test, 3-MT detected
by BDD at 16 ± 1 ng/mg protein and by carbon at 5.3 ± 0.3 ng/mg protein, P < 0.001).
One possible reason for these discrepancies in concentrations lies in the fact that the
BDD method was optimized for the simultaneous detection of DA and Ado and not for
the other monoamine or purine molecules, each of which has its own optimal oxidation
potential. To improve on the discrepancy in concentrations, the mobile-phase
configuration and working potential chosen for the BDD electrode should both be taken
into consideration. Although the primary focus was on separation and detection of DA
and Ado, we were still able to accurately quantify the monoamine and purine molecules
using the BDD electrode with good correlation with the porous carbon.
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Table 5.2 Comparison of BDD electrode and carbon electrode for the detection of
monoamine and purine molecules.
Monoamines
and Purines

Striatum
BDD

Striatum
Carbon

Frontal Cortex
BDD

Frontal
Cortex
Carbon

DA (ng/mg)

1190 ± 100

1310 ± 120

38 ± 10

22 ± 4

Ado (ng/mg)

1.40 x105 ± 1.7 x104

ND

1.28 x 105 ± 5.8 x 104

ND

210 ± 20

230 ± 50

35 ± 10

22 ± 5

3-MT (ng/mg)

63 ± 5

82 ± 10

16 ± 1

5.3 ± 0.3***

5-HIAA (ng/mg)

35 ± 8*

94 ± 20

31 ± 4

70 ± 20

5-HT (ng/mg)

160 ± 40

110 ± 20

60 ± 8

82 ± 20

NE (ng/mg)

130 ± 20

91 ± 20

115 ± 30

100 ± 8

1.19 x 106 ± 2.3 x 105

ND

1.57 x 106 ± 2.9 x 105

ND

DOPAC (ng/mg)

AMP (ng/mg)

Monoamine and purine tissue content levels measured as ng/mg protein.
ND = not detected. P values: *P < 0.05, ***P < 0.001, n values are 3–8 per set.
To further expand on our results with tissue-content, other studies were
examined with respect to tissue-content concentration. One caveat when comparing
tissue contents is the wide range of concentrations reported in the literature (Table 5.3),
emphasizing that tissue content measures relative differences and not absolute
neurotransmitter concentrations. There are numerous reasons for these discrepancies
in tissue-content neurotransmitter levels such as dissection techniques (free hand
versus punch), use of anesthesia prior to sacrifice, and time required to dissect the
tissue, as well as conditions used to store the tissue, buffer solutions used, and the type
of analysis for the tissue itself (164). In this study, tissue was normalized by using the
BCA protein method, while others have used wet weight, or a different protein assay
such as Lowry (45, 69, 86, 96, 160, 162, 165-169). Thus, despite these methodological
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differences for normalizing tissue, our tissue content neurotransmitter levels are well
within this wide range of values reported in the literature (Table 5.3).
Although our reported neurotransmitter levels are well within the documented
range, they do tend to be on the higher side. We believe this is a result of using female
C57BL6/J mice, because this was a proof-of-concept study and female mice were used
instead of male mice. Interestingly, the majority of tissue-content experiments
performed often examined only male mice or rats for their neurotransmitter levels.
Although few studies have examined female intracellular neurotransmitter levels, one
study showed that female mice have approximately twice as much striatal intracellular
DA as males with respect to tissue content (168). When the sex of the animal is taken
into consideration as well as differences in methodological conditions, these differences
could account for why our intracellular neurotransmitter values are on the higher end
compared to other values from the literature. With all these parameters considered, our
HPLC-BDD electrode method can measure monoamine and purine neurotransmitters
quickly and accurately.
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Table 5.3 Comparison of tissue content from the literature.
Brain
Region

Sex, Strain,
Species

DA

Ado

Method of
Quantification

Method of
Detection

Cerebral
cortex
(158)

Male Wistar
rats

N/A

265.6 ± 2.0
pmol/mg
wet tissue

Wet tissue
weight

HPLC-UV
photodiodearray

Frontal
Cortex
(163)

Albino mice

N/A

3075 ± 251
mmol/kg
protein

Lowry protein

HPLC-UV

Frontal
Cortex
(164)

Male
C57BL/6J
mice

~ 0.7 μg/g
wet tissue

N/A

Wet tissue
weight

HPLCelectrochemical

Prefrontal
Cortex
(165)

Male
C57Bl/6N
mice

~ 4 nM

N/A

No correction
for tissue
dissected

HPLCelectrochemical

Striatum
(158)

Male Wistar
rats

N/A

618.93 ± 2.0
pmol/mg
wet tissue

Wet tissue
weight

HPLC-UV
photodiodearray

Striatum
(47)

Male Wistar
rats

8.09 ± 2.1
μg/g wet
tissue

171.28 ±
57.78
μg/g ww

Wet tissue
weight

HPLC-UV and
electrochemical

Striatum
(88)

Male
C57BL/6J
mice

11,286.92 ±
478.42 pg/mg
ww

N/A

Wet weight

HPLCelectrochemical

Striatum
(164)

Male
C57BL/6J
mice

~ 14 μg/g
wet tissue

N/A

Wet tissue
weight

HPLCelectrochemical

Striatum
(160)

129 x
C57B/6

~ 550 ng/mg
protein

N/A

BCA protein

HPLCelectrochemical

Striatum
(166)

LRRK2
mice

246 ± 9
ng/mg protein

N/A

BCA protein

HPLC

Corpus
Striatum
(96)

Balb/c 129
strain

20437 ± 1395
pg/mg wet
tissue

N/A

Wet tissue
weight

HPLCelectrochemical

Corpus
Striatum
(93)

Male CD-1
mice

~ 6000 pg/mg
wet tissue

N/A

Wet tissue
weight

HPLCelectrochemical

Corpus
Striatum
(93)

Female CD1 mice

~ 15000
pg/mg wet
tissue

N/A

Wet tissue
weight

HPLCelectrochemical
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5.4 Conclusion
The advent of a commercially available BDD electrode has opened doors for
researchers to detect biological molecules with oxidation potentials greater than +1000
mV. In this work, we reported the first BDD electrode method to simultaneously detect
DA and Ado using HPLC with electrochemical detection. This BDD electrode method
measures DA and Ado in a single chromatogram in less than 8.5 min with excellent
accuracy and precision. Furthermore, the BDD method developed here can easily
separate and detect six other monoamines and two purine molecules with a run time of
~28 min. When this BDD method was compared to a similar method using a porous
carbon electrode, there was no difference between the quantified concentrations of
monoamine molecules from tissue-content samples. An advantage of the BDD working
electrode is that it can detect both Ado and AMP, which is not possible using the porous
carbon working electrode. This BDD method is effective for in vitro studies, and further
work is being done to develop it into a more sensitive method for in vivo microdialysis
samples. Taken together, our results demonstrate that the BDD electrode method is
easy to implement, detects analytes from the monoamine and purine family in a single
chromatogram, and accurately represents the tissue-content levels when compared to
the more traditional carbon electrode.
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CHAPTER 6
Conclusions and Future Directions
Brain-derived neurotrophic factor (BDNF) is an important neurotrophin in the
brain, and many studies have alluded to its importance for maintaining the structural
function and survival of dopamine (DA) neurons in the striatum (26, 28-30). Additionally,
irregularities within the DA system as well as BDNF expression have been identified in
neurological diseases and disorders such as Parkinson’s disease, Huntington’s disease,
schizophrenia, attention deficit hyperactivity disorder (ADHD), addiction, and depression
(1, 2, 27, 35, 110, 170-172). Furthermore, studies have indicated that there is an
increased risk for males developing neurological disorders such as Parkinson’s disease
as well as an earlier onset of the disease in comparison to woman (35, 173). To better
understand how lifelong low endogenous BDNF effects striatal DA dynamics, two of the
studies throughout this dissertation examined BDNF modulation of the striatal DA
system in both young (~3 months of age) female BDNF+/- mice and aged (~18 months
of age) BDNF+/- mice, Chapter 3 and Chapter 4, respectively. The overarching findings
from this dissertation demonstrate that a lifelong reduction in BDNF causes sex- and
age-dependent alterations in striatal DA dynamics in the striatum.
Therapeutic treatment for many of neurological diseases/disorders typically
focuses on the altered neurotransmitter system implicated in a given disease. For
example, Parkinson’s disease corresponds to a dysregulation of nigrostriatal DA, and
most treatment options focus on treating deficiencies in nigrostriatal DA for symptomatic
relief. L-3,4-Dihydroxyphenylalanine (L-DOPA), which is a precursor to DA synthesis,
enzymatic inhibitors that prevent the breakdown of DA such monoamine oxidase (MAO)
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inhibitors, and catechol-o-methyltransferase (COMT) inhibitors are used to treat motor
dysfunction associated with Parkinson’s disease (19). Although these treatments
decrease the adverse motor effects associated with Parkinson’s disease, they are also
associated with numerous side effects such as dyskinesia, hallucinations, and
eventually stop working completely. Thus, there is interest in finding new treatments
options. The adenosine (Ado) receptor A2A has received considerable attention because
A2A antagonists alleviate motor symptoms of Parkinson’s disease without causing the
side effects of the current treatment (20). Ado A2A receptors are highly expressed in DA
rich brain regions and have also been shown to co-localize with the DA D2 receptors
(174, 175). However, the in vivo function of Ado is not fully understood, which is in part
because there are few robust and sensitive analytical techniques to determine
extracellular Ado concentrations in the brain. Therefore, the third study in this
dissertation (Chapter 5) was to develop a method for the simultaneous detection of DA
and Ado. To date, this is the first method developed which utilizes high-performance
liquid chromatography (HPLC) with electrochemistry (a boron-doped diamond (BDD)
electrode) to detect DA and Ado, along with key members from their respective
neurotransmitter families.
6.1 Characterization of striatal dopamine dynamics in female BDNF+/- mice
Previous work conducted in the Mathews’ laboratory characterized the striatal DA
system in male BDNF+/- mice and their wildtype counterparts at 3–5 months of age, and
determined that the BDNF+/- mice were hyperdopaminergic in nature due to decreases
in their DA release and uptake (44). Our objective in this study was to determine if
female BDNF+/- mice are hyperdopaminergic as well or if BDNF modulates the DA
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system differently with respect to the female BDNF+/- mice. The goal was to determine if
the female BDNF+/- mice are hyperdopaminergic, and if so, what is the mechanism that
causes the hyperdopaminergia state, and is it the same as the male BDNF+/- mice?
Female BDNF+/- mice exhibited increased striatal extracellular DA levels in
comparison to their wildtype counterparts as measured by in vivo microdialysis
experiment of zero-net flux. This increase in extracellular DA levels was associated with
an increase in DA release as confirmed by three different experiments: electrically
stimulated DA release by fast scan cyclic voltammetry (FSCV), vesicular mediated
release by high potassium (K+) infusion with microdialysis, and pharmacological
mediated DA release with an injection of methamphetamine (METH). This
hyperdopaminergic state in the female BDNF+/- mice was not mediated by DA
metabolism, since no differences were observed between the genotypes, or via DA
uptake as measured by FSCV. We propose that the mechanism that causes the female
BDNF+/- mice to be hyperdopaminergic results from an overall potentiation in DA
release.

Interestingly,

young

male

BDNF+/-

mice

of

the

same

age

are

hyperdopaminergic but it is believed to be a result of a compensatory mechanism, as
young male BDNF+/- mice have both decreased DA uptake and release compared to
their wildtype controls (44). In male BDNF+/- mice, the DA striatal alterations have been
suggested as a result of a functional change in DAT, which decreases the rate of DA
uptake, leading to the elevation in extracellular DA levels.
Women are more likely to be afflicted by depression, stress, and anxiety
compared to men (36), and BDNF appears to be a central molecule in all of these
disorders. Therefore, the research conducted here was done to understand if female
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BDNF+/- mice exhibit different striatal DA dynamics compared to their male counterparts
that may make them more susceptible to depression, stress, and anxiety. Although mice
were not controlled for their estrous cycle, it does appear there is a significant difference
between male and female BDNF+/- mice regulating striatal DA, in particular DA release.
To better understand these complex interactions that may be a result of the differences
between the male and female BDNF+/- mice, estrogen application should be
investigated with respect to BDNF and DA. Previous work in our lab has examined the
effect of BDNF infusions on brain slices, where exogenous application of BDNF
increases stimulated DA release in the male BDNF+/- mice (44). Similarly future
experiments could evaluate independently the effect of estrogen and BDNF, alone and
in combination, which will provide valuable insight to how these neuromodulators
regulate striatal DA, specifically the mechanisms behind the increase in release in
females. Numerous studies have shown that both BDNF and estrogen modulate DA
release (44, 168, 176). However, it is imperative to understand their interactions in the
female BDNF+/- mice.
6.2 Characterization of a lifelong reduction of brain-derived neurotrophic factor
effects on the dopaminergic system in aged BDNF+/- mice
Parkinson’s disease is a debilitating disease, which manifest as a loss in motor
coordination corresponding to a loss of ~80% substantia nigra dopaminergic neurons.
Postmortem studies of Parkinson’s disease patient’s brains not only have decreases in
DA levels, but also in BDNF protein levels in the substantia nigra (SN) (5, 27). The goal
of this study was to determine if a lifelong reduction in BDNF levels negatively impacts
the striatal DA system. A previous study done in our lab using young (~3 month old)
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male BDNF+/- mice determined that they were hyperdopaminergic in nature (44). We
hypothesized that this hyperdopaminergia could be harmful as the animal progresses in
age because elevated extracellular DA levels in the striatum could lead to increases in
reactive oxygen species (ROS), leading to dopaminergic toxicity over the lifespan. A
combination of increased extracellular and intracellular DA levels produces ROS which
are hypothesized to induce irreversible damage to DA neurons (66, 125).
The results from our study indicate that aged (18 month old) BDNF+/- mice striatal
dopaminergic system appears to adjust to a lifelong reduction in BDNF. The
hyperdopaminergia that was observed in young BDNF+/- mice (Chapter 3 and (44)) is no
longer evident in the aged BDNF+/- mice. Extracellular DA levels in these aged
heterozygous mice are normalized to that of the wildtype mice, which is opposite of
what we hypothesized. In vivo microdialysis evaluation of basal extracellular DA levels
was determined to be not different among the aged BDNF+/- and wildtype mice. When
observing the basal DA levels between the young and aged BDNF+/- mice, aged
BDNF+/- mice basal DA levels have decreased to the levels shown in the young and
aged wildtype counterparts. Upon further analysis, this “normalization” of basal DA
levels in the aged BDNF+/- mice could be result of either (1) increased DA metabolism,
and/or (2) increased release and uptake of DA when compared to young BDNF+/- mice
(44). The results from this thesis showed that aged BDNF+/- mice have significantly
increased DA metabolism, which was demonstrated by an increase in basal levels of
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in comparison to
their aged wildtype mice. Stimulated DA release and uptake of DA were not different
between the aged genotypes, while these parameters were different in the young
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BDNF+/- mice. Young BDNF+/- mice had reduced DA release and DA uptake function
(44). Pharmacological stimulation of DA release using METH in the aged mice also
indicated that release was not different between genotypes. Although this study proved
our original hypothesis wrong that increases in extracellular DA in the young BDNF+/mice would be detrimental overtime (44). In fact, it appears that the DA system in the
BDNF+/- mice compensated for the increase in extracellular DA levels overtime, by
regulating striatal release and uptake as well as increasing DA metabolism.
In the future, more research should focus on fully understanding why the DA
system in the aged BDNF+/- mice eventually normalizes itself. BDNF protein levels in
aged BDNF+/- mice do not change over the lifespan of the animal (64). Therefore one
may speculate that other neurotrophic factors may be responsible and possibly
compensate for a system partially devoid of BDNF. A prime neurotrophic factor
candidate that may be responsible for possible compensatory actions may be
neurotrophin 4 (NT-4). To determine if this NT-4 hypothesis is correct further evaluation
of NT-4 levels and activity need to be determined in the aged BDNF+/- mice. Although
there are numerous neurotrophic factors that could be altered in BDNF+/- mice, NT-4
was chosen because it belongs to the same family of neurotrophic factors as BDNF and
it binds to the same receptor as BDNF, tyrosine kinase B (TrkB). In young BDNF+/mice, striatal NT-4 protein tissue levels are elevated in comparison to their wildtype
littermates, but striatal TrkB levels are unchanged (61), which suggests NT-4 levels are
altered and may be compensating for a 50% reduction of BDNF.
One of the most pressing issues to better understand is to determine the
mechanism behind the increase in DA metabolism of the aged BDNF+/- mice. Young
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BDNF+/- mice do not show an increase in metabolism, so over time DA metabolism
increases in BDNF+/- mice. Two enzymes that are responsible for the metabolism of DA
are MAO and COMT. From the microdialysis results that we garnered, it appears that
MAO activity or function is enhanced in the aged BDNF+/- mice since DOPAC levels are
increased, and therefore, future work should evaluate their function and expression
6.3 Simultaneous detection of dopamine and adenosine using HPLC with
electrochemical detection using a boron-doped diamond electrode
The objective of this work was to develop a method which could detect DA and
Ado simultaneously using HPLC with a BDD electrode. Typically, monoamine molecules
are detected using electrochemical detection because they are easily oxidized. Purine
molecules such as Ado are also electrochemically active, but oxidize at potentials
greater than +1000 mV at a carbon surface with respect to a Ag/AgCl reference
electrode. However, potentials greater than +1000 mV are often not possible with
carbon electrodes because of the structural damage to the carbon surface (49). To
circumvent this problem, a newly commercially available BDD electrode has been
developed to be used with HPLC instrumentation. The BDD electrode is advantageous
because it has a large potential working range (up to +2000 mV), lower background
noise, and is less susceptible to electrode fouling (51, 73). In this project, the BDD
electrode was utilized in conjunction with an HPLC instrument to develop a method for
the simultaneous detection of DA and Ado. This BDD method was able to accurately
separate and detect six monoamine and two purine molecules in about 28 min with
good separation. When a proof-of-concept study evaluated and compared the
neurotransmitter levels from tissue-content samples from the striatum and frontal cortex
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of mice with a porous carbon electrode or BDD electrode coupled to an HPLC
instrument, the BDD electrode method detected and quantify monoamine levels that
corresponded to the levels detected with the carbon electrode. However, the advantage
of the BDD electrode was its ability to also detect Ado and adenosine monophosphate
(AMP), which were not detected at the carbon electrode.
The in vivo function of Ado is not well understood, and that is mainly because of
a lack of reliable methods to routinely detect low levels of Ado. Current methods show
extracellular levels of Ado to be between 40–240 nM in the striatum, a range that is far
too large (14, 68, 160, 161). Furthermore, there is increasing evidence of DA and Ado
interacting in the striatum. To truly understand these interactions with respect to DA and
Ado levels, future work with will take this method and refine and apply it to detect
extracellular DA and Ado levels, which are about a 100-fold less than tissue content
samples. If this BDD method proves successful at measuring baseline DA and Ado
levels via microdialysis, it will provide a much more user-friendly method to measure
extracellular Ado levels. Currently, our BDD method is good enough for the detection of
Ado in vivo, but not for DA. We believe to achieve DA detection, the column must be
similar to the one that we currently use for routine dialysis experiments; one with a
smaller particle size or a shorter column length, since decreasing these parameters will
increase peak height and sensitivity. The length of the column dictates the flow of
analyte and sample capacity while the size of the particles in the column control column
efficiency and increase peak height due to its direct correlation to mass transfer of the
analyte through the column. By decreasing the particle size or the column length may
lead to further modifications/refinements of the mobile phase. However, we believe
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these adjustments will not require a complete revamp of the current mobile phase and
that in vivo detection of Ado and DA at a BDD electrode surface is just around the
corner.
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ABSTRACT
INVESTIGATION OF DOPAMINE DYNAMICS IN BDNF+/- MICE USING IN VIVO
MICRODIALYSIS
AND
ELECTROCHEMICAL ANALYSIS OF PURINE AND MONOAMINE MOLECULES
USING A BORON-DOPED DIAMOND ELECTRODE
by
JOHNNA ANN BIRBECK
August 2013
Advisor: Tiffany A. Mathews
Major: Chemistry (Analytical)
Degree: Doctor of Philosophy
The goal of the first study was to determine if a reduction in brain-derived
neurotrophic factor (BDNF) levels in female mice lead to a dysregulation in their
dopaminergic system. Through a series of in vivo microdialysis and slice voltammetry
experiments, we have discerned that female BDNF+/- mice are hyperdopaminergic
similar to their male BDNF+/- counterparts. The in vivo microdialysis method zero-net flux
highlighted that female BDNF+/- mice had increased extracellular dopamine (DA) levels,
while stimulated regional release by high potassium potentiated DA release from
vesicular mediated depolarization. Using the complementary technique of fast scan
cyclic voltammetry, electrical stimulation evoked greater release in the female BDNF+/mice, while uptake was not different from female wildtype mice. When the
psychostimulant methamphetamine was administered, female BDNF+/- mice had
potentiated DA release compared to their wildtype counterparts. Taken together, the DA
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release impairments in female mice appears to result in a hyperdopaminergic
phenotype with no concomitant alterations in DA uptake.
The aim of the second study was to characterize how lifelong reductions in BDNF
affect the striatal dopaminergic system in aged BDNF+/- mice. As BDNF+/- mice aged
from 3 to 18 months, their striatal dopamine dynamics, as measured by microdialysis
and slice voltammetry, ‘normalized’ with respect to time. Aged BDNF+/- mice (18
months) had elevated levels of striatal DA metabolites and decreased phasic versus
tonic release of DA with time. DA levels in BDNF+/- mice were age-dependent such that
low BDNF levels in early adulthood, as previously reported, led to a hyperdopaminergic
state while DA dynamics in the aged BDNF+/- mice

‘normalized’ with no overt

alterations in either behavior or neurochemistry.
In the third study we developed a method using a commercially available BDD
working electrode for detecting neurotransmitters from two different families with large
oxidation

potential

differences,

DA

and

adenosine

(Ado).

Hydrodynamic

voltammograms were constructed for DA and Ado, and the optimal potential for
detection of DA and Ado was determined to be +740 mV and +1200 mV versus a
palladium reference electrode, respectively. A working potential of +840 mV was chosen
and the detection range achieved with the BDD electrode for DA and Ado was from low
nanomolar to high millimolar levels. To determine the practical function of the BDD
electrode, tissue content was analyzed for seven monoamines and two purine
molecules, which were resolved in a single run in less than 28 min. Our results
demonstrate that the BDD electrode is sensitive and robust enough to detect
monoamine and purine molecules from frontal cortex and striatal mouse samples.
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